☐
|
REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
|
☒
|
ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Shares, no par value
|
TMDI
|
The NASDAQ Stock Market LLC
|
☒
|
Annual information form
|
☒
|
Audited annual financial statements
|
|
• |
the Company’s technology and research and development objectives, including development milestones, estimated costs, schedules for completion and probability of success;
|
|
• |
the Company’s intention with respect to updating any forward‑looking statement after the date on which such statement is made or to reflect the occurrence of unanticipated events;
|
|
• |
the Company’s business plan consists of the development of robotic-assisted surgical technologies for application in minimally invasive surgery (“MIS”) comprising its Enos
system;
|
|
• |
the Enos system under development includes a surgeon-controlled patient cart that includes a 3D high definition vision system and multi-articulating instruments for performing MIS procedures;
|
|
• |
the Enos system under development includes a surgeon workstation that provides the surgeon with an ergonomic interface to the patient cart and a 3D high-definition view of the MIS procedures;
|
|
• |
the Company’s intent to initially pursue gynecologic surgical indications for use of its Enos system;
|
|
• |
the Company’s plan to continue development of a robust training curriculum and post-training assessment tools for surgeons and surgical teams;
|
|
• |
the training curriculum, which is planned to include cognitive pre-training, psychomotor skills training, surgery simulations, live animal and human cadaver lab training, surgical team training, troubleshooting
and an overview of safety;
|
|
• |
post-training assessment, which will include validation of the effectiveness of those assessment tools;
|
|
• |
the Company will likely proceed with a De Novo classification submission for the Enos system, while continuing to evaluate its options for use of the 510(k) submission pathway;
|
|
• |
the Company’s intention to continue with the De Novo classification process if the 510(k) submission pathway is not available to the Company or would otherwise present other difficulties;
|
|
• |
the outcome of any review by the FDA and the time required to complete activities necessary for regulatory approval or clearance;
|
|
• |
the Company’s plans on further communications with the FDA and to file additional Pre-Submissions to clarify the requirements for the IDE clinical study protocol and understand any special controls which the FDA
may apply;
|
|
• |
the performance of human surgeries with the Enos system will require an Investigational Device Exemption (“IDE”) from the Food and Drug Administration (“FDA”), which must be submitted and approved in advance;
|
|
• |
the recruitment of surgeons from multiple hospital sites will be necessary to perform the surgeries. Each of these sites will require approval of their independent Institutional Review Board (“IRB”) to approve the studies;
|
|
• |
an application to the IRB of each hospital will be made once the FDA has approved the Company’s IDE application;
|
|
• |
the Company’s intention to submit to the FDA an application for marketing authorization upon successful completion of the IDE clinical study;
|
|
• |
the Company’s ability to secure required capital to fund development and operating costs in a timely manner;
|
|
• |
actual costs and development times, which will exceed those previously set forth by the Company in years prior to 2020;
|
|
• |
the fact that the Company cannot produce an accurate estimate of the future costs of the development milestones and regulatory phases for the Enos system beyond the year 2022;
|
|
• |
the Company’s technology and research and development objectives and milestones, including any estimated costs, schedules for completion and probability of success and including without limitation the table set
forth herein under the heading, “Development Plan” in the AIF, and the footnotes thereunder;
|
|
• |
the indication of additional specific milestones as the development of the Enos system progresses;
|
|
• |
the Company’s plan to further expand its patent portfolio by filing additional patent applications as it progresses in the development of robotic-assisted surgical technologies and, potentially, by licensing
suitable technologies;
|
|
• |
the Company’s intention to secure additional financing to continue the Company’s research and development program through to completion and take advantage of future opportunities;
|
|
• |
the Company’s expectation that it will be able to finance its continuing operations by accessing public markets for its securities;
|
|
• |
the Company’s intention with respect to not paying any cash dividends on the Company’s common shares (the “Common Shares”) in the foreseeable future; and
|
|
• |
the Company’s intention to retain future earnings, if any, to finance expansion and growth.
|
|
• |
the Company will require additional financing which may not be available to us on acceptable terms, or at all;
|
|
• |
the Company has a history of losses and there is no guarantee that the Company will be able to achieve profitability;
|
|
• |
the Company relies on contractual arrangements and there can be no assurance that these arrangements will achieve their goals;
|
|
• |
the Company depends on key personnel and the loss of the service of such personnel could have a negative impact on the Company’s business;
|
|
• |
the Company expects to increase the size of the Company’s management team in the future and the Company’s failure to attract and retain new members of the Company’s management team could adversely affect the
Company’s business;
|
|
• |
the Company’s trade secrets or other confidential information may be compromised;
|
|
• |
the Company relies on third parties for a number of important aspects of the Company’s business and there are a range of issues that are outside of the Company’s direct control;
|
|
• |
the Company’s industry is highly competitive, and a number of the Company’s competitors have significantly greater financial and human resources than the Company;
|
|
• |
the Company’s commercial success depends significantly on the Company’s ability to operate without infringing the patents and other proprietary rights of third parties;
|
|
• |
should the Company be unable to obtain and enforce its patent rights, the Company’s business could be materially harmed;
|
|
• |
the Company may be unable to obtain or maintain the Company’s trademarks and may incur substantial costs attempting to defend and enforce the Company’s rights in this regard;
|
|
• |
certain of the Company’s directors and officers also serve as directors and/or officers of other companies, creating the possibility that a conflict of interest could arise;
|
|
• |
the Company’s financial results and results of operations have fluctuated in the past and may continue to be volatile going forward;
|
|
• |
the Company is targeting a rapidly evolving robotic assisted surgical device market, and it is not clear that surgeons or hospitals will choose the Enos system over those offered by the Company’s competitors;
|
|
• |
the introduction of more technologically advanced products and/or new entrants to the market could impact the Company’s operating and financial results;
|
|
• |
the Company may become subject to potential product liability claims, and the Company may be required to pay damages that exceed the Company’s insurance coverage;
|
|
• |
the Company’s technology may depend on third party licenses for certain functions or procedures and there can be no guarantee that the Company will be able to secure and maintain those licenses;
|
|
• |
government and agency regulation controls all aspects of the Company’s product and business, and changes in policies and additional regulations may be enacted that could prevent or delay regulatory clearance or
approval of the Company’s products;
|
|
• |
should the Company be granted FDA marketing authorization, the Company may subsequently decide to make certain modifications to the Company’s products for a number of reasons including those based on customer
feedback and/or in view of competitive offerings;
|
|
• |
a recall of the Company’s products, either voluntarily or at the direction of the FDA or another governmental authority or regulatory body, or the discovery of serious safety issues with the Company’s products,
could have a significant adverse impact on the Company;
|
|
• |
compliance with accounting regulations and tax rules across multiple jurisdictions is resource intensive and expensive and could expose the Company to penalties and fines;
|
|
• |
contingent liabilities could have a negative impact on the Company’s financial position;
|
|
• |
there can be no certainty that the Company will meet the Company’s established product development and commercialization milestones, and failure to do so may affect the Company’s operational and financial results;
|
|
• |
Commercial manufacturing of the Enos system is expected to be an extremely detailed and complex process with the potential for delays, interruptions, or cost overruns;
|
|
• |
the Company’s reliance on suppliers and development firms for execution of the Company’s development programs means that the Company do not control all aspects of the development;
|
|
• |
a product malfunction, including in any clinical studies, could result in delays, liability and negative perceptions of the Enos system and the Company;
|
|
• |
certain reusable instruments, camera components and other accessories require repeated cleaning and sterilization;
|
|
• |
as the Company is a Canadian company, it may be difficult for U.S. shareholders to effect service on the Company or to realize on judgments obtained in the U.S.;
|
|
• |
the Company is subject to risks related to additional regulatory burden and controls over financial reporting;
|
|
• |
fluctuations in foreign currency exchange rates may adversely affect the Company’s financial results;
|
|
• |
the Company may not be able to maintain the Company’s status as a “Foreign Private Issuer”;
|
|
• |
the Company is an “emerging growth company” and cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make it less attractive to investors;
|
|
• |
the Company is likely a “passive foreign investment company”, which may have adverse U.S. federal income tax consequences for U.S. investors;
|
|
• |
the Company may face or otherwise be exposed to cyber-security risks and threats;
|
|
• |
the Company’s financial condition and results of operations for fiscal 2021 may be adversely affected by the global COVID-19 pandemic;
|
|
• |
the global COVID-19 pandemic creates substantial uncertainty as to the willingness and ability of hospitals, health maintenance organizations (HMOs), ambulatory care facilities and other prospective customers to
purchase and implement robotic surgical systems; and
|
|
• |
material weaknesses in the Company’s internal controls over financial reporting.
|
|
• |
general business and current global economic conditions;
|
|
• |
future success of current research and development activities;
|
|
• |
achieving development milestones;
|
|
• |
ability to achieve product cost targets;
|
|
• |
competition;
|
|
• |
no significant changes to regulatory clearance or approval processes in the United States and Europe;
|
|
• |
stable tax rates and benefits;
|
|
• |
the availability of financing on a timely basis;
|
|
• |
the Company’s and competitors’ costs of production and operations;
|
|
• |
the Company’s ability to attract and retain skilled employees;
|
|
• |
the Company’s ongoing relations with its third-party service providers;
|
|
• |
the design of the Enos system and related platforms and equipment;
|
|
• |
the progress and timing of the development of the Enos system;
|
|
• |
costs related to the development of the Enos system;
|
|
• |
receipt of all applicable regulatory approvals or clearances;
|
|
• |
estimates and projections regarding the robotic-assisted surgery equipment industry;
|
|
• |
protection of the Company’s intellectual property rights;
|
|
• |
market acceptance of the Company’s systems under development;
|
|
• |
the Company’s ability to meet the continued listing standards of NASDAQ and the TSX; and
|
|
• |
the type of specialized skill and knowledge required to develop the Enos system and the Company’s access to such specialized skill and knowledge.
|
|
a) |
the Company did not have sufficient accounting resources with relevant technical accounting skills to address issues relating to the assessment of IFRS treatment for complex accounting issues, specifically
relating to a material amendment to a contract with an external development firm;
|
|
b) |
the Company did not have sufficient accounting resources with relevant technical accounting skills to address and review issues relating to the valuation of warrant liabilities; and
|
|
c) |
the Company did not sufficiently design internal controls to provide the appropriate level of oversight regarding the financial recordkeeping and review of the Company’s cut-off procedures as they relate to
accounts payable and valuation of supplier liabilities.
|
|
a) |
engagement of one or more qualified and independent consulting firms with subject matter experts to assist with the Company’s internal accounting and reporting over complex accounting issues;
|
|
b) |
institution of business systems to support the work associated with the valuation and reporting of the warrant liabilities and other equity-based securities; and
|
|
c) |
engagement of an external consulting firm to assist with increasing the Company’s in-house resources to increase the number of qualified personnel involved in financial accounting and reporting.
|
|
• |
reviewing compensation payable to the Chief Executive Officer of the Company and other executives;
|
|
• |
reviewing the compensation payable to directors;
|
|
• |
overseeing the administration of compensation plans;
|
|
• |
reviewing executive and director compensation disclosure to be made in the proxy circular prepared in connection with the Company’s annual meeting of shareholders; and
|
|
• |
reviewing the Company’s compensation standards, along with management’s annual recommendations, to ensure each are consistent with each other and currently appropriate.
|
TITAN MEDICAL INC.
|
||||
|
|
|
||
By:
|
|
/s/ Monique L. Delorme
|
||
Name: Monique L. Delorme
|
|
|||
|
Title: Chief Financial Officer
|
Exhibit Number
|
Description
|
101.INS
|
XBRL Instance
|
101.SCH
|
XBRL Taxonomy Extension Schema
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase
|
Exhibit 99.1
|
|
|
1
|
|
1
|
|
1
|
|
1
|
|
1
|
|
5
|
|
5
|
|
15
|
|
15
|
|
16
|
|
17
|
|
19
|
|
20
|
|
20
|
|
20
|
|
34
|
|
35
|
|
36
|
|
36
|
|
38
|
|
39
|
|
39
|
|
40 | |
40
|
|
43
|
|
44
|
|
45
|
|
45
|
|
46
|
|
46
|
|
46
|
|
46
|
|
47
|
|
47
|
|
47
|
|
47
|
|
47
|
|
EXPERTS
|
48
|
48
|
|
|
|
• |
the Company’s technology and research and development objectives, including development milestones, estimated costs, schedules for completion and probability of success;
|
|
• |
the Company’s intention with respect to updating any forward‑looking statement after the date on which such statement is made or to reflect the occurrence of unanticipated events;
|
|
• |
the Company’s business plan consists of the development of robotic-assisted surgical technologies for application in minimally invasive surgery (“MIS”) comprising its Enos system;
|
|
• |
the Enos system under development includes a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures;
|
|
• |
the Enos system under development includes a surgeon workstation that provides the surgeon with an ergonomic interface to the patient cart and a 3D high-definition view of the MIS procedures;
|
|
• |
the Company’s intent to initially pursue gynecologic surgical indications for use of its Enos system;
|
|
• |
the Company’s plan to continue development of a robust training curriculum and post-training assessment tools for surgeons and surgical teams;
|
|
• |
the training curriculum, which is planned to include cognitive pre-training, psychomotor skills training, surgery simulations, live animal and human cadaver lab training, surgical team training, troubleshooting
and an overview of safety;
|
|
|
|
• |
post-training assessment, which will include validation of the effectiveness of those assessment tools;
|
|
• |
the Company will likely proceed with a De Novo classification submission for the Enos system, while continuing to evaluate its options for use of the 510(k) submission pathway;
|
|
• |
the Company’s intention to continue with the De Novo classification process if the 510(k) submission pathway is not available to the Company or would otherwise present other difficulties;
|
|
• |
the outcome of any review by the Food and Drug Administration of the United States Department of Health and Human Services (the “FDA”) and the time required to complete activities necessary for regulatory
approval or clearance;
|
|
• |
the Company’s plans on further communications with the FDA and to file additional Pre-Submissions to clarify the requirements for the IDE clinical study protocol and understand any special controls which the
FDA may apply;
|
|
• |
the performance of human surgeries with the Enos system will require an Investigational Device Exemption (“IDE”) from the FDA, which must be submitted and approved in advance;
|
|
• |
the recruitment of surgeons from multiple hospital sites will be necessary to perform the surgeries. Each of these sites will require approval of their independent Institutional Review Board (“IRB”) to approve
the studies;
|
|
• |
an application to the IRB of each hospital will be made once the FDA has approved the Company’s IDE application;
|
|
• |
the Company’s intention to submit to the FDA an application for marketing authorization upon successful completion of the IDE clinical study;
|
|
• |
the Company’s ability to secure required capital to fund development and operating costs in a timely manner;
|
|
• |
actual costs and development times, which will exceed those previously set forth by the Company in years prior to 2020;
|
|
• |
the fact that the Company cannot produce an accurate estimate of the future costs of the development milestones and regulatory phases for the Enos system beyond the year 2022;
|
|
• |
the Company’s technology and research and development objectives and milestones, including any estimated costs, schedules for completion and probability of success and including without limitation the table set
forth herein under the heading, “Development Plan” and the footnotes thereunder;
|
|
• |
the indication of additional specific milestones as the development of the Enos system progresses;
|
|
• |
the Company’s plan to further expand its patent portfolio by filing additional patent applications as it progresses in the development of robotic-assisted surgical technologies and, potentially, by licensing
suitable technologies;
|
|
• |
the Company’s intention to secure additional financing to continue the Company’s research and development program through to completion and take advantage of future opportunities;
|
|
• |
the Company’s expectation that it will be able to finance its continuing operations by accessing public markets for its securities;
|
|
• |
the Company’s intention with respect to not paying any cash dividends on the Company’s common shares (the “Common Shares”) in the foreseeable future; and
|
|
• |
the Company’s intention to retain future earnings, if any, to finance expansion and growth.
|
|
• |
the Company will require additional financing which may not be available to us on acceptable terms, or at all;
|
|
• |
the Company has a history of losses and there is no guarantee that the Company will be able to achieve profitability;
|
|
• |
the Company relies on contractual arrangements and there can be no assurance that these arrangements will achieve their goals;
|
|
• |
the Company depends on key personnel and the loss of the service of such personnel could have a negative impact on the Company’s business;
|
|
|
|
• |
the Company expects to increase the size of the Company’s management team in the future and the Company’s failure to attract and retain new members of the Company’s management team could adversely affect the
Company’s business;
|
|
• |
the Company’s trade secrets or other confidential information may be compromised;
|
|
• |
the Company relies on third parties for a number of important aspects of the Company’s business and there are a range of issues that are outside of the Company’s direct control;
|
|
• |
the Company’s industry is highly competitive, and a number of the Company’s competitors have significantly greater financial and human resources than the Company;
|
|
• |
the Company’s commercial success depends significantly on the Company’s ability to operate without infringing the patents and other proprietary rights of third parties;
|
|
• |
should the Company be unable to obtain and enforce its patent rights, the Company’s business could be materially harmed;
|
|
• |
the Company may be unable to obtain or maintain the Company’s trademarks and may incur substantial costs attempting to defend and enforce the Company’s rights in this regard;
|
|
• |
certain of the Company’s directors and officers also serve as directors and/or officers of other companies, creating the possibility that a conflict of interest could arise;
|
|
• |
the Company’s financial results and results of operations have fluctuated in the past and may continue to be volatile going forward;
|
|
• |
the Company is targeting a rapidly evolving robotic assisted surgical device market, and it is not clear that surgeons or hospitals will choose the Enos system over those offered by the Company’s competitors;
|
|
• |
the introduction of more technologically advanced products and/or new entrants to the market could impact the Company’s operating and financial results;
|
|
• |
the Company may become subject to potential product liability claims, and the Company may be required to pay damages that exceed the Company’s insurance coverage;
|
|
• |
the Company’s technology may depend on third party licenses for certain functions or procedures and there can be no guarantee that the Company will be able to secure and maintain those licenses;
|
|
• |
government and agency regulation controls all aspects of the Company’s product and business, and changes in policies and additional regulations may be enacted that could prevent or delay regulatory clearance or
approval of the Company’s products;
|
|
• |
should the Company be granted FDA marketing authorization, the Company may subsequently decide to make certain modifications to the Company’s products for a number of reasons including those based on customer
feedback and/or in view of competitive offerings;
|
|
• |
a recall of the Company’s products, either voluntarily or at the direction of the FDA or another governmental authority or regulatory body, or the discovery of serious safety issues with the Company’s products,
could have a significant adverse impact on the Company;
|
|
• |
compliance with accounting regulations and tax rules across multiple jurisdictions is resource intensive and expensive and could expose the Company to penalties and fines;
|
|
• |
contingent liabilities could have a negative impact on the Company’s financial position;
|
|
• |
there can be no certainty that the Company will meet the Company’s established product development and commercialization milestones, and failure to do so may affect the Company’s operational and financial
results;
|
|
• |
Commercial manufacturing of the Enos system is expected to be an extremely detailed and complex process with the potential for delays, interruptions, or cost overruns;
|
|
• |
the Company’s reliance on suppliers and development firms for execution of the Company’s development programs means that the Company do not control all aspects of the development;
|
|
• |
a product malfunction, including in any clinical studies, could result in delays, liability and negative perceptions of the Enos system and the Company;
|
|
• |
certain reusable instruments, camera components and other accessories require repeated cleaning and sterilization;
|
|
• |
as the Company is a Canadian company, it may be difficult for U.S. shareholders to effect service on the Company or to realize on judgments obtained in the U.S.;
|
|
• |
the Company is subject to risks related to additional regulatory burden and controls over financial reporting;
|
|
• |
fluctuations in foreign currency exchange rates may adversely affect the Company’s financial results;
|
|
• |
the Company may not be able to maintain the Company’s status as a “Foreign Private Issuer”;
|
|
|
|
• |
the Company is an “emerging growth company” and cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make it less attractive to investors;
|
|
• |
the Company is likely a “passive foreign investment company”, which may have adverse U.S. federal income tax consequences for U.S. investors;
|
|
• |
the Company may face or otherwise be exposed to cyber-security risks and threats;
|
|
• |
the Company’s financial condition and results of operations for fiscal 2021 may be adversely affected by the global COVID-19 pandemic;
|
|
• |
the global COVID-19 pandemic creates substantial uncertainty as to the willingness and ability of hospitals, health maintenance organizations (HMOs), ambulatory care facilities and other prospective customers
to purchase and implement robotic surgical systems; and
|
|
• |
material weaknesses in the Company’s internal controls over financial reporting.
|
|
• |
general business and current global economic conditions;
|
|
• |
future success of current research and development activities;
|
|
• |
achieving development milestones;
|
|
• |
ability to achieve product cost targets;
|
|
• |
competition;
|
|
• |
no significant changes to regulatory clearance or approval processes in the United States and Europe;
|
|
• |
stable tax rates and benefits;
|
|
• |
the availability of financing on a timely basis;
|
|
• |
the Company’s and competitors’ costs of production and operations;
|
|
• |
the Company’s ability to attract and retain skilled employees;
|
|
• |
the Company’s ongoing relations with its third-party service providers;
|
|
• |
the design of the Enos system and related platforms and equipment;
|
|
• |
the progress and timing of the development of the Enos system;
|
|
• |
costs related to the development of the Enos system;
|
|
• |
receipt of all applicable regulatory approvals or clearances;
|
|
• |
estimates and projections regarding the robotic-assisted surgery equipment industry;
|
|
• |
protection of the Company’s intellectual property rights;
|
|
• |
market acceptance of the Company’s systems under development;
|
|
• |
the Company’s ability to meet the continued listing standards of Nasdaq and the TSX; and
|
|
• |
the type of specialized skill and knowledge required to develop the Enos system and the Company’s access to such specialized skill and knowledge.
|
|
|
Medtronic Milestone(1)
|
Deadline(2)
|
Payment
(US$)(3) |
Medtronic Milestone 1
|
Four (4) months from Development Start Date(4) (5)
|
$10,000,000
|
Medtronic Milestone 2(6)
|
Four (4) months from Development Start Date
|
-
|
Medtronic Milestone 3
|
Six (6) months from the later of (a) receipt by us of Payment for Medtronic Milestone 1, (b) receipt by us from Medtronic of Medtronic deliverables
required for Medtronic Milestone 3, and (c) receipt by us from Medtronic of confirmation of certain due diligence in respect of our deliverables for Medtronic Milestone 1
|
$10,000,000
|
Medtronic Milestone 4
|
Four (4) months from the later of (a) receipt by us of Payment for Medtronic Milestone 3, (b) receipt by us of Medtronic deliverables for
Medtronic Milestone 4, and (c) receipt by us from Medtronic of confirmation of certain due diligence in respect of our deliverables for Medtronic Milestone 3
|
$11,000,000 (7) (8)
|
|
(1) |
Medtronic Milestone 1, Medtronic Milestone 3 and Medtronic Milestone 4 are each defined in the Development Agreement and consist of the completion of the development of certain robotic assisted surgical
technologies as described in the Development Agreement.
|
|
(2) |
All as further described and qualified in the Development Agreement.
|
|
(3) |
Each payment is conditional upon the corresponding milestone being completed on a timely basis.
|
|
(4) |
“Development Start Date” has the meaning ascribed to it in the Development Agreement and as set out above.
|
|
(5) |
As of the date of hereof, Medtronic Milestone 1 has been achieved on schedule and payment was received.
|
|
(6) |
Medtronic Milestone 2 is a non-technology milestone defined as Titan raising at least US $18,000,000 of capital between the effective date of the Development Agreement and the date that is four months from the
Development Start Date. Medtronic Milestone 2 was achieved ahead of the deadline in June 2020.
|
|
(7) |
The amount of the payment will be the sum of US $10,000,000 and the amount of certain legal, transaction and intellectual property related expenses to be paid to the Company up to a maximum of US $1,000,000
pursuant to the Development Agreement and License Agreement.
|
(8)
|
The balance outstanding under the Medtronic Loan (described below) will be offset against the payment for Medtronic Milestone
|
|
|
|
|
|
|
|
a) |
the Company did not have sufficient accounting resources with relevant technical accounting skills to address issues relating to the assessment of IFRS treatment for complex accounting issues,
specifically relating to a material amendment to a contract with an external development firm;
|
|
b) |
the Company did not have sufficient accounting resources with relevant technical accounting skills to address and review issues relating to the valuation of warrant liabilities; and
|
|
c) |
the Company did not sufficiently design internal controls to provide the appropriate level of oversight regarding the financial recordkeeping and review of the Company’s cut-off procedures as they relate
to accounts payable and valuation of supplier liabilities.
|
|
a) |
engagement of one or more qualified and independent consulting firms with subject matter experts to assist with the Company’s internal accounting and reporting over complex accounting issues;
|
|
b) |
institution of business systems to support the work associated with the valuation and reporting of the warrant liabilities and other equity-based securities; and
|
|
c) |
engagement of an external consulting firm to assist with increasing the Company’s in-house resources to increase the number of qualified personnel involved in financial accounting and reporting.
|
|
|
|
|
|
|
|
• |
Florida Hospital Nicholson Center in Celebration, Florida;
|
|
• |
Columbia University Medical Center in New York, New York; and
|
|
• |
Institut hospitalo-universitaire de Strasbourg (“IHU Strasbourg”) in Strasbourg, France.
|
|
|
|
|
•
|
Gynecological and gynecological oncology (8 procedures at Columbia University (New York City) (“Columbia University”) and Florida Hospital’s Nicholson Center (Celebration, Florida) (“Florida Hospital”):
|
|
•
|
Radical Hysterectomy with Bilateral Salpingo Oophorectomy and Bilateral Pelvic / Para‑Aortic Node Dissection
|
|
•
|
Simple Hysterectomy with Bilateral Salpingo Oophorectomy and Bilateral Pelvic Node Dissection
|
|
•
|
Simple Hysterectomy with Bilateral Salpingo Oophorectomy
|
•
|
Urology (19 procedures at the Institut hospitalo‑universitaire (Strasbourg, France) (“IHU Strasbourg”) and Florida Hospital):
|
•
|
Hemi‑Nephrectomy and Partial Nephrectomy
|
|
•
|
Prostatectomy (Human Cadaver)
|
|
•
|
Pyeloplasty
|
|
•
|
Ureteral‑Bladder Anastomosis
|
•
|
General Surgery (14 procedures at IHU Strasbourg and Florida Hospital):
|
•
|
Cholecystectomy (1 Human Cadaver, 5 Live Porcine)
|
|
•
|
Nissen Fundoplication (1 Human Cadaver, 3 Live Porcine)
|
|
•
|
Esophagectomy (Human Cadaver)
|
|
•
|
Gastrectomy
|
|
•
|
Splenectomy
|
•
|
Colorectal (4 procedures at Florida Hospital):
|
•
|
Colectomy
|
|
•
|
Low Anterior Resection
|
1. |
Multi‑disciplinary applications of a new robotic platform by Barbara Seeliger, MD and Lee Swanstrom, MD (IHU Strasbourg). Accepted and presented at Society of American Gastrointestinal and
Endoscopic Surgeons Meeting, Seattle, WA, April 2018.
|
2. |
Single‑port prostatectomy using SPORT Surgical System by Eric Barret, MD (IMM, France). Accepted and presented at EAU Section of Urology Technology Meeting, Modena, Italy, May 2018.
|
3. |
Multispecialty single port robotic technology applied in the live animal model: proof of concept by Travis Rogers, MD, Eduardo Parra Davila, MD, Vipul Patel, MD (all from Florida Hospital),
Ricardo Estape, MD (South Miami GOG) and Armando Melani, MD (IRCAD Brazil). Accepted and presented as a poster at Society of Robotic Surgery Meeting, Stockholm, Sweden, June 2018.
|
|
|
4. |
Feasibility of single‑port partial nephrectomy using SPORT surgical system by Eric Barret, MD (IMM, France). Accepted and presented as a poster at Society of Robotic Surgery Meeting, Stockholm,
Sweden, June 2018.
|
5. |
Single‑port robotic partial and hemi nephrectomy using a novel single port robotic platform by Sebastien Crouzet, MD (University of Lyon, France) and Barbara Seeliger, MD (IHU Strasbourg).
Accepted and presented at EAU Robotic Urology Section Meeting, Marseille, France, September 2018.
|
6. |
Reverse Objective Structured Assessment of Technical Skills (Reverse‑OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles by
Chetna Arora, MD, Arnold P. Advincula, MD (both from Columbia University Medical Center) and William B. Burke, MD (Stony Brook Cancer Center). Accepted and presented at Society of European Robotic Gynecologic Surgeons Meeting,
Milan, Italy, September 2018.
|
7. |
Multispecialty single port robotic technology applied in the live animal model: proof of concept by Travis Rogers, MD, Eduardo Parra Davila, MD, Vipul Patel, MD (all from Florida Hospital),
Ricardo Estape, MD (South Miami GOG) and Armando Melani, MD (IRCAD Brazil). Accepted and presented at World Congress of Endourology Meeting, Paris, France, September 2018.
|
8. |
Feasibility of single‑port partial nephrectomy using SPORT surgical system by Eric Barret, MD (IMM, France). Accepted and presented at World Congress of Endourology Meeting, Paris, France,
September 2018.
|
9. |
Reverse Objective Structured Assessment of Technical Skills (Reverse‑OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles by
Chetna Arora, MD, Arnold P. Advincula, MD (both from Columbia University Medical Center) and William B. Burke, MD (Stony Brook Cancer Center). Accepted and presented at American Association of Gynecologic Laparoscopists Global
Congress, Las Vegas, NV, November 2018.
|
|
|
|
|
|
|
|
|
Milestone Number
|
Development Milestones
|
Estimated
Cost (US million $)(1) |
Schedule for Milestone Completion
|
Comments
|
Milestone 1(4)
|
Design, prototype and test improvements to instruments, cameras and CDU
|
3.2
|
Q4 2020
|
Completed
|
Milestone 2(4)
|
Launch rebranded product line including logos with trademark pending, literature and presentation templates and new website
|
0.3
|
Q4 2020
|
Completed
|
Milestone 3(4)
|
Iterate electromechanical design, update sterile adaptors and drape
|
5.2
|
Q1 2021
|
Completed
|
Milestone 4(4)
|
Perform additional software development and test system performance
|
5.4
|
Q1-Q2 2021
|
-
|
Milestone 5(4)
|
Perform animal lab assessment
|
0.1
|
Q2 2021
|
-
|
Milestone 6(4)
|
Perform biocompatibility testing of instruments, camera systems and accessories at independent lab
|
3.8
|
Q2 2021
|
-
|
Milestone 7(4)
|
Perform electrical safety testing for surgeon workstations and patient cart, including electromagnetic compatibility (EMC) and electromagnetic interference (EMI) tests at independent lab
|
2.7
|
Q3 2021
|
-
|
Milestone 8(4)
|
Perform animal feasibility or GLP study
|
2.8
|
Q3 2021
|
-
|
Milestone 9(2)
|
Complete initial build of Enos system IDE units
|
10.2
|
Q4 2021
|
-
|
Milestone 10(2)(4)
|
Complete system verification testing
|
3.3
|
Q4 2021
|
-
|
Milestone 11(2)(4)
|
Complete HFE summative testing
|
1.9
|
Q4 2021
|
-
|
Milestone 12
|
Update application for IDE as additional testing lab data is received and continue preparation for human confirmatory studies
|
6.0
|
Q1 2022
|
-
|
|
|
Milestone Number
|
Development Milestones
|
Estimated
Cost (US million $)(1) |
Schedule for Milestone Completion
|
Comments
|
Milestone 13
|
Submit IDE application to FDA
|
6.0
|
Q1 2022
|
-
|
Milestone 14
|
Complete secondary build of Enos system IDE units
|
|||
Milestone 15
|
Initiate IDE clinical study
|
19.0
|
Q2-Q4 2022
|
-
|
Milestone 16
|
Complete IDE clinical study, data analysis and final report
|
|||
Milestone 17(3)
|
Submit application for FDA marketing authorization
|
TBD
|
TBD(5)
|
-
|
Milestone 18
|
Tentative FDA marketing authorization letter
|
TBD
|
TBD
|
-
|
|
(1) |
The estimated costs above include an allocation of US $1.8-2.8 million per quarter of general and administrative costs.
|
|
(2) |
Milestones 9, 10 and 11 are expected to be executed during the fourth quarter of 2021 with their projected completion in December 2021. If the Company achieves Medtronic Milestones 3 and 4, it
will be entitled to receive the corresponding payments from Medtronic of US $10 million and US $11 million, respectively, and, in those circumstances the Company estimates that it will have sufficient funds for the execution and
completion of Milestones 9, 10 and 11. If the Company does not achieve Medtronic Milestones 3 and 4, the Company will need to raise additional capital to complete Milestones 9, 10 and 11.
|
|
(3) |
The Company plans to submit its application for FDA marketing authorization at a future date, after successful completion of IDE clinical studies and following further correspondence with the FDA
as described in the section titled “Description of the Business – Regulatory”.
|
|
(4) |
The costs of Milestones 1 through 11 are forecasted to total US $38.9 million, a net increase of US $1.6 million from amounts previously forecasted and published in the Company’s Management
Discussion and Analysis dated November 16, 2020. The increase is primarily related to general and administrative costs, enhancing internal R&D capabilities and other general R&D related costs.
|
|
|
|
|
|
|
|
• |
the successful development of its first-generation product in a form that is competitive in features, performance, and price;
|
|
• |
the successful identification and development of new products for its core market;
|
|
• |
its ability to anticipate customer and market requirements and changes in technology and industry standards in a timely manner;
|
|
• |
its ability to gain access to and use technologies in a cost-effective manner;
|
|
• |
its ability to introduce cost-effective new products in a timely manner;
|
|
• |
its ability to differentiate its products from its competitors’ offerings;
|
|
• |
its ability to gain customer acceptance of its products;
|
|
• |
the performance of its products relative to its competitors’ products;
|
|
• |
its ability to market and sell its products through effective sales channels;
|
|
• |
its ability to establish and maintain effective internal financial and accounting controls and procedures;
|
|
• |
its ability to obtain required regulatory clearances and approvals in a timely manner;
|
|
• |
the protection of its intellectual property, including its processes, trade secrets and know-how; and
|
|
• |
its ability to attract and retain qualified technical, executive and sales personnel.
|
|
|
|
|
|
• |
the successful development and commercialization of the single-port robotic surgical system in a timely manner and in accordance with budgeted expenditures;
|
|
• |
actions relating to regulatory matters;
|
|
• |
timing and ability to develop manufacturing and sales and marketing capabilities;
|
|
• |
demand for robotic surgical systems in general;
|
|
• |
the extent to which its products gain market acceptance;
|
|
• |
the progress of surgical training in the use of products;
|
|
• |
ability to develop, introduce and market new or enhanced versions of its products on a timely basis;
|
|
• |
product quality problems or alleged product quality problems;
|
|
• |
ability to protect proprietary rights and defend against third party challenges; and
|
|
• |
ability to license additional intellectual property rights as required.
|
|
|
|
|
|
• |
a medical device candidate may not be deemed safe or effective, in the case of a PMA application;
|
|
• |
a medical device candidate may not be deemed to be substantially equivalent to a device lawfully marketed either as a grandfathered device or one that was cleared through the 510(k)
premarket notification process;
|
|
• |
a medical device candidate may not be deemed to demonstrate that (i) general controls or general and special controls are adequate to provide reasonable assurance of safety and
effectiveness, and (ii) the probable benefits of the device outweigh the probable risks, each in the case of a De Novo classification request;
|
|
• |
a medical device candidate may not be deemed to be in conformance with applicable standards and regulations;
|
|
• |
regulatory officials may not find the data from preclinical and clinical studies sufficient;
|
|
• |
regulatory authorities might not approve its processes or facilities or those of any of its third-party manufacturers; or
|
|
• |
regulatory authorities may change clearance or approval policies or adopt new regulations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
• |
present and future demand for robotic surgeries, equipment and related products;
|
|
• |
its ability to complete pre-clinical and clinical trials of its robotic system and to obtain regulatory approvals as required on a timely basis; and
|
|
• |
the ability of its suppliers and development partners to provide goods and services and other resources in a timely manner to support its business including its work
toward achievement of its development, regulatory and commercialization milestones.
|
|
|
Warrant
|
Issue Date
|
Expiry Date
|
Number Issued
|
Number Outstanding
|
Exercise Price US $
|
Exercise Price CDN $
|
TMD.WT.G
|
12-Feb-16
|
12-Feb-21
|
389,027
|
386,694
|
$30.00
|
|
TMD.WT.G
|
23-Feb-16
|
12-Feb-21
|
58,226
|
58,226
|
$30.00
|
|
TMD.WT.H
|
31-Mar-16
|
31-Mar-21
|
501,831
|
501,831
|
$36.00
|
|
TMD.WT.H
|
14-Apr-16
|
31-Mar-21
|
75,275
|
75,275
|
$36.00
|
|
TMD.WT.I
|
20-Sep-16
|
20-Sep-21
|
569,444
|
569,444
|
$22.50
|
|
TMD.WT.I
|
27-Oct-16
|
20-Sep-21
|
67,667
|
67,667
|
$22.50
|
|
Not Listed
|
16-Mar-17
|
16-Mar-21
|
357,787
|
355,253
|
$15.00
|
|
Not Listed
|
29-Jun-17
|
29-Jun-22
|
1,612,955
|
75,810
|
$6.00
|
|
Not Listed
|
21-Jul-17
|
29-Jun-22
|
370,567
|
370,567
|
$6.00
|
|
Not Listed
|
24-Aug-17
|
24-Aug-22
|
563,067
|
563,067
|
$6.00
|
|
Not Listed
|
05-Dec-17
|
05-Dec-22
|
1,533,333
|
1,533,333
|
$18.00
|
|
Not Listed
|
10-Apr-18
|
10-Apr-23
|
1,126,665
|
1,126,665
|
$10.50
|
|
Not Listed
|
10-May-18
|
10-Apr-23
|
168,889
|
168,889
|
$10.50
|
|
Not Listed1
|
10-Aug-18
|
10-Aug-23
|
7,679,574
|
6,661,068
|
$2.920
|
|
Not Listed2
|
21-Mar-19
|
21-Mar-24
|
8,455,882
|
8,455,882
|
$3.950
|
|
Not Listed
|
27-Mar-20
|
27-Mar-25
|
3,500,000
|
-
|
$0.190
|
|
Not Listed
|
06-May-20
|
06-Nov-25
|
2,757,252
|
-
|
$0.3002
|
|
Not Listed
|
10-Jun-20
|
10-Jun-24
|
9,000,000
|
8,000,000
|
$1.00
|
|
39,021,181
|
28,969,671
|
|
(1) |
Note 1 - Includes a ratchet clause triggered August 29, 2019 lowering the exercise price from $3.20 to $2.92.
|
|
(2) |
Note 2 - Includes a ratchet clause triggered August 29, 2019 lowering the exercise price from $4.00 to $3.95.
|
|
|
TSX
|
Nasdaq
|
|||||
Month
|
High (CDN $)
|
Low (CDN $)
|
Volume
|
High (US $)
|
Low (US $)
|
Volume
|
January
|
0.98
|
0.61
|
1,511,067
|
0.73
|
0.46
|
8,537,585
|
February
|
0.69
|
0.48
|
886,752
|
0.53
|
0.35
|
4,902,858
|
March
|
0.64
|
0.15
|
3,135,116
|
0.45
|
0.12
|
77,716,212
|
April
|
0.56
|
0.25
|
2,141,538
|
0.41
|
0.18
|
27,393,353
|
May
|
0.47
|
0.31
|
2,181,952
|
0.34
|
0.22
|
44,936,077
|
June
|
2.34
|
0.36
|
21,451,006
|
1.75
|
0.26
|
190,677,088
|
July
|
1.44
|
1.01
|
2,493,086
|
1.08
|
0.75
|
42,171,080
|
August
|
1.19
|
0.92
|
1,054,766
|
0.93
|
0.7
|
14,494,065
|
September
|
1.16
|
0.75
|
1,228,709
|
0.9
|
0.57
|
10,361,281
|
October
|
1.09
|
0.92
|
683,717
|
0.83
|
0.69
|
7,034,141
|
November
|
1.81
|
0.86
|
2,372,867
|
1.4
|
0.6539
|
20,172,366
|
December
|
2.60
|
1.47
|
4,136,613
|
2.04
|
1.15
|
33,167,559
|
|
|
Month
|
High (CDN $)
|
Low (CDN $)
|
Volume
|
January
|
0.015
|
0.005
|
274,825
|
February
|
0.010
|
0.005
|
383,600
|
March
|
0.010
|
0.005
|
28,000
|
April
|
0.005
|
0.005
|
0
|
May
|
0.005
|
0.005
|
8,000
|
June
|
0.030
|
0.005
|
1,064,400
|
July
|
0.010
|
0.010
|
98,089
|
August
|
0.010
|
0.005
|
34,000
|
September
|
0.005
|
0.005
|
10,000
|
October
|
0.040
|
0.005
|
220,000
|
November
|
0.010
|
0.005
|
62,000
|
December
|
0.005
|
0.005
|
197,020
|
|
|
Month
|
High (CDN $)
|
Low (CDN $)
|
Volume
|
January
|
0.010
|
0.005
|
319,000
|
February
|
0.010
|
0.005
|
339,000
|
March
|
0.005
|
0.005
|
1,000
|
April
|
0.005
|
0.005
|
0
|
May
|
0.005
|
0.005
|
0
|
June
|
0.030
|
0.005
|
1,098,000
|
July
|
0.005
|
0.005
|
1,000
|
August
|
0.005
|
0.005
|
1,000
|
September
|
0.005
|
0.005
|
0
|
October
|
0.015
|
0.005
|
232,000
|
November
|
0.005
|
0.005
|
8,000
|
December
|
0.005
|
0.005
|
6,000
|
|
|
Month
|
High (CDN $)
|
Low (CDN $)
|
Volume
|
January
|
0.030
|
0.010
|
23,500
|
February
|
0.010
|
0.010
|
191,000
|
March
|
0.010
|
0.005
|
137,200
|
April
|
0.010
|
0.005
|
134,000
|
May
|
0.010
|
0.005
|
479,333
|
June
|
0.030
|
0.005
|
428,000
|
July
|
0.020
|
0.020
|
45,650
|
August
|
0.020
|
0.005
|
961,500
|
September
|
0.010
|
0.005
|
47,250
|
October
|
0.015
|
0.005
|
207,398
|
November
|
0.020
|
0.005
|
185,000
|
December
|
0.030
|
0.005
|
253,539
|
Date
|
Exercise Price per
Common Shares |
Number of Common
Shares Exercisable |
March 27, 2020
|
US $0.1900
|
3,500,000
|
May 6, 2020
|
US $0.3002
|
2,757,252
|
June 10, 2020
|
US $1.0000
|
3,250,000
|
June 10, 2020
|
US $0.0001
|
11,500,000
|
June 10, 2020
|
US $1.0000
|
5,750,000
|
Date
|
Exercise Price
|
Number of Stock Options Granted
|
March 7, 2020
|
US $0.2125
|
490,000
|
May 6, 2020
|
US $0.4534
|
386,015
|
June 10, 2020
|
US $1.2500
|
1,260,000
|
Date
|
Exercise Price
|
Number of Stock Options Granted
|
July 30, 2020
|
CDN $1.266
|
22,425
|
July 30, 2020
|
US $0.9622
|
1,350,000
|
September 29, 2020
|
CDN $0.96
|
27,304
|
September 29, 2020
|
US $0.7300
|
19,568
|
September 30, 2020
|
US $0.7450
|
4,723
|
December 10, 2020
|
CDN $1.7000
|
4,000
|
December 10, 2020
|
US $1.3100
|
623,000
|
|
|
Name and
Municipality and
Country of Residence
|
Offices Held
|
Director
Since
|
Principal Occupation(s) During the
Five-Year Period Ending December 31, 2020
|
David J. McNally
Salt Lake City, Utah,
U.S.A. |
President, Chief Executive Officer and Chairman
|
2017
|
Chief Executive Officer and President of Titan from January 3, 2017, and January 9, 2017, respectively. Chairman of the Board of Titan from June 4, 2020. Prior
thereto, from October 2009 to August 2016, Mr. McNally served as the founder, President, Chief Executive Officer and Chairman of the Board of Directors of Domain Surgical, Inc., a privately held
developer, manufacturer and marketer of a new advanced energy surgery platform for precise cutting and coagulation of soft tissue, and reliable vessel sealing in open and laparoscopic procedures.
Domain Surgical, Inc. was merged with OmniGuide Holdings, Inc. in August 2016.
|
Monique L. Delorme
Toronto, Ontario, Canada
|
Chief Financial Officer
|
NA
|
Chief Financial Officer of Titan from October 2020 to the present. VP Finance of Titan from July 2020 to September 2020. Controller of Titan from March 2019 to July
2020. Chief Financial Officer of Northern Sphere Mining Corp. from April 2017 to June 2020. Chief Financial Officer of Zonetail Inc. from September 2015 to October 2017.
|
Perry Genova
Chapel Hill, North Carolina, U.S.A.
|
Senior Vice President, Research and Development, and President of Titan Medical USA Inc.
|
NA
|
Senior Vice President, Research and Development of Titan from February 2017 to present. Chief Executive Officer of Centauri Surgical from February 2016 to February
2017. Chief Executive Officer of Oncoscope Inc. from September 2009 to January 2016.
|
|
|
Name and
Municipality and
Country of Residence
|
Offices Held
|
Director
Since
|
Principal Occupation(s) During the
Five-Year Period Ending December 31, 2020
|
Curtis Jensen
Gig Harbor, Washington State, U.S.A.
|
Vice President, Quality and Regulatory Affairs
|
NA
|
Vice President, Quality and Regulatory Affairs from April 2017 to present. Senior Regulatory Affairs Associate at Ekos Corporation from December 2015 to April 2017.
|
Jasminder Brar
Toronto, Ontario, Canada
|
Vice President, Legal, IP and Strategic Initiatives, General Counsel and Corporate Secretary
|
NA
|
Vice President, Legal, IP and Strategic Initiatives, General Counsel and Corporate Secretary from June 2020 to present. Director of Strategic Development and IP
Counsel from May 2011 to June 2020.
|
Paul Cataford(1), (2), (3)
Calgary, Alberta, Canada
|
Lead Independent Director, Audit Committee Chair
|
2020
|
Chief Executive Officer of Zephyr Sleep Technologies Inc. from September 2010 to present.
|
Anthony J. Giovinazzo(1), (2), (3)
Carlisle, Ontario, Canada
|
Director, Governance/Nominating Committee Chair
|
2020
|
Chief Executive Officer of Cynapsus Therapeutics Inc. from October 2009 to October 2016. Director of Promis Neurosciences from March 2017 to September 2020. Director
of Pond Technologies Inc. from November 2020 to present.
|
Cary G. Vance(1), (2), (3)
Lehi, Utah, U.S.A.
|
Director, Compensation Committee Chair
|
2020
|
Chief Executive Officer of XCath Inc. from October 2020 to present. Chief Executive Officer of OptiScan Biomedical from May 2018 to June 2020. Chief Executive Officer
of MyoScience Inc. from April 2017 to May 2018. Chief Executive Officer of Hansen Medical from May 2014 to August 2016.
|
Stephen Randall
Toronto, Ontario,
Canada |
Director
|
2017
|
Chief Financial Officer of Titan from March 2010 to September 2020.
|
|
(1) |
Member of the Audit Committee
|
|
(2) |
Member of the Compensation Committee
|
|
(3) |
Member of the Corporate Governance and Nominating Committee
|
|
|
|
1. |
none of the directors or executive officers of the Company, or any person or company that beneficially owns, or controls or directs, directly or indirectly, more than
10% of any class or series of the Company’s outstanding voting securities, or any associate or affiliate of any of the foregoing persons or companies is, at the date hereof, or has within 10 years
before the date hereof, been a director, chief executive officer or chief financial officer of any other issuer that (a) was the subject of a cease trade, an order similar to a cease trade order or an
order that denied the issuer access to any statutory exemptions under securities legislation, that was in effect for a period of more than 30 consecutive days (an “Order”), that, while that person was
acting in the capacity as a director, chief executive officer or chief financial officer, or (b) was subject to an order that was issued after that person ceased to be a director, chief executive
officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as a director, chief executive officer or chief financial officer;
|
|
2. |
none of the directors or executive officers of the Company, or any person or company that beneficially owns, or controls or directs, directly or indirectly, more than
10% of any class or series of the Company’s outstanding voting securities, or any associate or affiliate of any of the foregoing persons or companies (a) is, at the date hereof, or has within 10 years
before the date hereof, been a director or executive officer of any other issuer that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity,
became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver,
manager or trustee appointed to hold its assets, or (b) has, within 10 years before the date hereof, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was
subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, manager or trustee appointed to hold its assets; and
|
|
3. |
none of the directors or executive officers of the Company, or any person or company that beneficially owns, or controls or directs, directly or indirectly, more than
10% of any class or series of the Company’s outstanding voting securities, or any associate or affiliate of any of the foregoing persons or companies has been subject to (a) any penalties or sanctions
imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority, or (b) any other
penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.
|
|
|
|
|
|
|
|
|
Director
|
Independent
|
Financially Literate
|
|
Paul Cataford
Mr. Cataford has served as an independent corporate director for a number of public companies. He holds a Bachelor of Science degree in Mechanical Engineering
from Queen’s University, an MBA specializing in Finance from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College,
Rotman School of Business at the University of Toronto.
|
Yes
|
Yes
|
|
Anthony J. Giovinazzo
Mr. Giovinazzo previously served as Chief Executive Officer and director of Cynapsus Therapeutics Inc. Mr. Giovinazzo has a Chartered Director (C.Dir.) and
Audit Committee Certification (ACC) from The Directors College and the DeGroote School of Business at McMaster University. He received a Bachelor of Arts degree in Economics and Accounting
from McMaster University and an MBA from IMD Geneva, Switzerland.
|
Yes
|
Yes
|
|
Cary G. Vance
Mr. Vance previously served in executive and director roles at several issuers. Mr. Vance is Lean/Six Sigma Black Belt certified, and earned a Bachelor of Arts
degree in Economics and an MBA from Marquette University.
|
Yes
|
Yes
|
Financial Year Ended
|
Audit Fees(1)
|
Audit‑Related Fees(2)
|
Tax Fees(3)
|
All Other Fees(4)
|
December 31, 2020
|
70,779
|
37,064
|
7,058
|
47,855
|
December 31, 2019
|
62,281
|
59,344
|
4,888
|
116,893
|
|
(1) |
“Audit Fees” are fees billed by the Company’s external auditor for services provided in auditing the Company’s financial statements for the financial year.
|
|
(2) |
“Audit‑Related Fees” are fees not included in Audit Fees that are billed by the auditor for assurance and related services that are reasonably related to
performing the audit or reviewing the Company’s interim financial statements.
|
|
(3) |
“Tax Fees” are fees billed by the auditor for professional services rendered for tax compliance, tax advice and tax planning.
|
|
(4) |
“All Other Fees” are fees billed by the auditor for products and services not included in the previous categories. These fees relate primarily to the work
performed by the Company’s external auditor in conjunction with filings by the Company of prospectus and registration statements with securities regulators in Canada and the United states in
respect of public and registered offerings completed by Titan in 2019 and 2020.
|
|
|
|
1. |
the Warrant Indentures described under the section “Capital Structure”;
|
|
2. |
the Aspire Agreement;
|
|
3. |
the Second Aspire Agreement;
|
|
4. |
the Development Agreement;
|
|
5. |
the License Agreement; and
|
|
6. |
the Note.
|
|
|
|
|
|
• |
financial reporting;
|
|
• |
the external auditors, including performance, qualifications, independence, and their audit of the Company's financial statements;
|
|
• |
internal controls and disclosure controls;
|
|
• |
financial risk management;
|
|
• |
the Company's Code of Conduct (the "Code"); and
|
|
• |
related party transactions.
|
|
|
|
|
|
1. |
General Responsibilities
|
|
a. |
Create and maintain a Committee plan for the year.
|
|
b. |
Review and assess this Charter at least annually, prepare revisions to its provisions as conditions dictate, and refer its assessment and any proposed
revisions to the Corporate Governance and Nominating Committee or the Board.
|
|
c. |
Report and make recommendations periodically to the Board on the matters covered by this Charter.
|
|
d. |
Perform any other activities consistent with this Charter, the Company's Articles and By- Laws and governing law, as the Audit Committee or the Board of
Directors deems necessary or appropriate.
|
|
2. |
Financial Reporting
|
|
a. |
Recommend, to the Board, for approval:
|
|
i. |
the Company's annual and interim financial statements and related MD&A;
|
|
ii. |
all other financial statements that require approval by the Board, including financial statements for use in prospectuses or other offering or public
disclosure documents and financial statements required by regulatory authorities; and
|
|
iii. |
financial information for use in press releases, including annual and interim profit or loss press releases, prior to their publication and/or filing with
any governmental body and/or release.
|
|
|
|
b. |
Notwithstanding, part (a), approve:
|
|
i. |
the Company's interim financial statements and related MD&A; and
|
|
ii. |
financial information for use in press releases related to interim profit or loss press releases, prior to their publication and/or filing with any
governmental body and/or release.
|
|
c. |
Overseeing the work of the external auditor engaged for the purpose of preparing or issuing an auditor's report or performing other audit, review or attest
services for the Company, including the resolution of disagreements between management and the external auditor regarding financial reporting.
|
|
d. |
Before the release of financial statements and related disclosures to the public, obtain confirmation from the CEO and CFO as to the matters addressed in
the certifications required by the securities regulatory authorities.
|
|
e. |
Review any litigation, claim or other contingency that could have a material effect on the financial statements.
|
|
f. |
Review the external auditors' judgments about the quality and appropriateness, not just the acceptability, of the Company's accounting principles and
financial disclosure practices, as applied in its financial reporting.
|
|
g. |
Review the status of significant accounting estimates and judgments and special issues (e.g., major transactions, changes in the selection or application of
accounting policies, off- balance sheet items, effect of regulatory and financial initiatives).
|
|
h. |
Review and approve, if appropriate, major changes to the Company's accounting principles and practices as suggested by management with the concurrence of
the external auditors.
|
|
3. |
External Auditor
|
|
a. |
Responsible for (i) the selection of the external auditors, considering independence and effectiveness; and (ii) the fees and other compensation to be paid
to the external auditors.
|
|
b. |
Require, in accordance with applicable law, that the external auditors report directly to the Audit Committee.
|
|
c. |
Review the annual audit plan with the external auditors and pre-approve all audit and non-audit services to be provided to the Company or its subsidiaries
by the external auditors in a manner consistent with NI 52-110.
|
|
d. |
Oversee the work and review the performance of the external auditors and approve any proposed discharge of the external auditors when circumstances warrant.
|
|
e. |
Monitor the relationship between management and the external auditors, including reviewing any management letters or other reports of the external auditors.
|
|
f. |
Discuss with the external auditor any (i) difference of opinion with management on material auditing or accounting issues, and (ii) any audit problems or
difficulties experienced by the external audit in performing the audit. Where there are significant unsettled issues, the Audit Committee is to assist in arriving at an agreed course of
action for the resolution of such matters.
|
|
g. |
Periodically consult with the external auditors without management present about significant risks or exposures, internal controls and other steps that
management has taken to control such risks, and the completeness and accuracy of the Company's financial statements. Particular emphasis should be given to the adequacy of internal
controls to expose any payments, transactions, or procedures that might be deemed illegal or otherwise improper.
|
|
|
|
h. |
Review and discuss, on an annual basis, with the external auditors all significant relationships they have with the Company to determine their independence.
|
|
i. |
Review and approve the Company’s hiring policies regarding partners, employees and former partners and employees of the Company's external auditors.
|
|
j. |
Consider any matter required to be communicated to the Audit Committee by the external auditors under applicable generally accepted auditing standards,
applicable law and listing standards, including the auditor's report to the Audit Committee (and management's response thereto).
|
|
4. |
Monitoring Financial Matters, Internal Controls, Management Systems and Disclosure Controls
|
|
a. |
Oversee management's review of the adequacy of the Company's accounting and financial reporting systems, including with respect to the integrity and quality
of the Company's financial statements and other financial information.
|
|
b. |
Oversee management's review of the adequacy of the Company's internal controls and management systems to safeguard assets from loss and unauthorized use and
to verify the accuracy of the financial records.
|
|
c. |
In consultation with the Corporate Governance and Nominating Committee, oversee management's disclosure controls and procedures regarding the Company's
financial information to confirm that the Company's financial information that is required to be disclosed under applicable law or stock exchange rules is disclosed.
|
|
d. |
Review any special audit steps adopted in light of material control deficiencies.
|
|
5. |
Risk Management
|
|
a. |
Review management's assessment and management of financial risk, including insurance coverage, and obtain the external auditors' opinion of management's
assessment of significant financial risks facing the Company and how effectively such risks are being managed or controlled.
|
|
6. |
Code of Conduct
|
|
a. |
Recommend to the Board any significant changes to the Code, monitor compliance with the Code and ensure that management has established a system to enforce
the Code. Review appropriateness of actions taken to ensure compliance with the Code and review the results of confirmations and violations thereof.
|
|
b. |
Oversee procedures in the Code for (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal controls or
auditing matters, and (ii) the confidential, anonymous submission by employees of concerns regarding questionable accounting or auditing matters.
|
|
c. |
Approve any waiver from compliance with the Code for directors and executive officers, promptly report any such waiver to the Board, and ensure appropriate
disclosure of any such waiver.
|
|
7. |
Related Party Transactions
|
|
a. |
Review and pre-approve all proposed related party transactions and situations involving a potential or actual conflict of interest involving a director,
member of executive management, or affiliate, that are not required to be dealt with by an "independent committee" pursuant to securities laws, other than routine transactions and
situations arising in the ordinary course of business, consistent with past practice.
|
|
|
|
8. |
Financial Legal Compliance
|
|
a. |
Review management's monitoring of the Company's systems in place to ensure that the Company's financial statements, reports and other financial information
disseminated to governmental organizations and the public satisfy legal requirements.
|
|
b. |
Review with legal counsel any legal matters that could have a significant effect on the Company's financial statements.
|
|
c. |
Review with legal counsel the Company's compliance with applicable law and inquiries received from regulators and governmental agencies to the extent they
may have a material impact on the financial position of the Company.
|
|
9. |
Expense Accounts and Management Perquisites
|
|
a. |
Recommend to the Board policies and procedures with respect to directors' and executive management's expense accounts and management perquisites and
benefits, including their use of corporate assets and expenditures related to executive travel and entertainment, and review the results of the procedures performed in these areas by the
external auditors.
|
|
10. |
Succession Planning
|
|
a. |
Consult with the Compensation Committee and Corporate Governance and Nominating Committee on succession planning for the directors and executive management.
|
|
11. |
Disclosure of Audit Committee Function
|
|
a. |
Oversee the preparation of, and recommend to the Board, the disclosure of the Audit Committee's composition and responsibilities and how they were
discharged as required to be published annually in the Company's management information circular or annual information form pursuant to applicable law (including NI 52-110).
|
|
b. |
Approve any other significant information relating to matters within this Charter contained in the Company's disclosure documents.
|
|
12. |
Legal Compliance
|
|
a. |
Oversee management's compliance with laws with respect to the audit function, and recommend to the Board any changes to the Company's practices in these
areas.
|
|
b. |
Satisfy itself that management monitors significant trends in the area of financial reporting, and evaluates their impact on the Company.
|
|
|
|
a. |
Working with the Board Chair, the Chief Executive Officer and the Corporate Secretary to establish the frequency of Committee meetings and the agendas for
such meetings.
|
|
b. |
Providing leadership to the Committee and presiding over Committee meetings.
|
|
c. |
Facilitating the flow of information to and from the Committee and fostering an environment in which the Committee members may ask questions and express
their viewpoints.
|
|
d. |
Reporting to the Board with respect to the significant activities of the Committee and any recommendations made by the Committee.
|
|
e. |
Annually assess the effectiveness of the Committee, soliciting input from all Committee members.
|
|
f. |
Pre-approve audit and non-audit services not already included in the Committee pre-approved audit plan, with any such decisions to be presented to the full
Committee at its next regularly scheduled meeting.
|
|
g. |
Taking such other steps as are reasonably required to ensure that the Committee carries out this Charter.
|
|
h. |
Carry out any other duties and responsibilities delegated by the Committee or assigned by the Board.
|
|
a. |
The Committee shall have the resources and authority appropriate to discharge its duties and responsibilities, including the authority to:
|
|
i. |
engage, select, retain, terminate, set and approve the fees and other compensation and other retention terms of special or independent counsel, accountants
or other advisors, as it deems appropriate;
|
|
ii. |
obtain appropriate funding to pay, or approve the payment of, such approved fees, at the expense of the Company; and
|
|
iii. |
communicate directly with the internal and external auditors.
|
|
|
1. |
An audit committee member is independent if he or she has no direct or indirect material relationship with the issuer.
|
2. |
For the purposes of subsection (1), a "material relationship" is a relationship which could, in the view of the issuer's board of directors, be reasonably
expected to interfere with the exercise of a member's independent judgement.
|
3. |
Despite subsection (2), the following individuals are considered to have a material relationship with an issuer:
|
|
a. |
an individual who is, or has been within the last three years, an employee or executive officer of the issuer;
|
|
b. |
an individual whose immediate family member is, or has been within the last three years, an executive officer of the issuer;
|
|
c. |
an individual who:
|
|
i. |
is a partner of a firm that is the issuer's internal or external auditor,
|
|
ii. |
is an employee of that firm, or
|
|
iii. |
was within the last three years a partner or employee of that firm and personally worked on the issuer's audit within that time;
|
|
d. |
an individual whose spouse, minor child or stepchild, or child or stepchild who shares a home with the individual:
|
|
i. |
is a partner of a firm that is the issuer's internal or external auditor,
|
|
ii. |
is an employee of that firm and participates in its audit, assurance or tax compliance (but not tax planning) practice, or
|
|
iii. |
was within the last three years a partner or employee of that firm and personally worked on the issuer's audit within that time;
|
|
e. |
an individual who, or whose immediate family member, is or has been within the last three years, an executive officer of an entity if any of the issuer's
current executive officers serves or served at that same time on the entity's compensation committee; and
|
|
f. |
an individual who received, or whose immediate family member who is employed as an executive officer of the issuer received, more than $75,000 in direct
compensation from the issuer during any 12-month period within the last three years.
|
4. |
Despite subsection (3), an individual will not be considered to have a material relationship with the issuer solely because
|
|
a. |
he or she had a relationship identified in subsection (3) if that relationship ended before March 30, 2004; or
|
|
b. |
he or she had a relationship identified in subsection (3) by virtue of subsection (8) if that relationship ended before June 30, 2005.
|
|
|
5. |
For the purposes of clauses (3) (c) and (3) (d), a partner does not include a fixed income partner whose interest in the firm that is the internal or
external auditor is limited to the receipt of fixed amounts of compensation (including deferred compensation) for prior service with that firm if the compensation is not contingent in any
way on continued service.
|
6. |
For the purposes of clause (3) (t), direct compensation does not include:
|
|
a. |
remuneration for acting as a member of the board of directors or of any board committee of the issuer, and
|
|
b. |
the receipt of fixed amounts of compensation under a retirement plan (including deferred compensation) for prior service with the issuer if the compensation
is not contingent in any way on continued service.
|
7. |
Despite subsection (3), an individual will not be considered to have a material relationship with the issuer solely because the individual or his or her
immediate family member
|
|
a. |
has previously acted as an interim chief executive officer of the issuer, or
|
|
b. |
acts, or has previously acted, as a chair or vice-chair of the board of directors or of any board committee of the issuer on a part-time basis.
|
8. |
For the purpose of this section I, an issuer includes a subsidiary entity of the issuer and a parent of the issuer.
|
1. |
Despite any determination made under section I, an individual who
|
|
a. |
accepts, directly or indirectly, any consulting, advisory or other compensatory fee from the issuer or any subsidiary entity of the issuer, other than as
remuneration for acting in his or her capacity as a member of the board of directors or any board committee, or as a part-time chair or vice-chair of the board or any board committee; or
|
|
b. |
is an affiliated entity of the issuer or any of its subsidiary entities, is considered to have a material relationship with the issuer.
|
2. |
For the purposes of subsection (1), the indirect acceptance by an individual of any consulting, advisory or other compensatory fee includes acceptance of a
fee by
|
|
a. |
an individual's spouse, minor child or stepchild, or a child or stepchild who shares the individual's home; or
|
|
b. |
an entity in which such individual is a partner, member, an officer such as a managing director occupying a comparable position or executive officer, or
occupies a similar position (except limited partners, non-managing members and those occupying similar positions who, in each case, have no active role in providing services to the entity)
and which provides accounting, consulting, legal, investment banking or financial advisory services to the issuer or any subsidiary entity of the issuer.
|
3. |
For the purposes of subsection (1), compensatory fees do not include the receipt of fixed amounts of compensation under a retirement plan (including
deferred compensation) for prior service with the issuer if the compensation is not contingent in any way on continued service.
|
Exhibit 99.2
|
|
Tel: 416 865 0200
Fax: 416 865 0887
www.bdo.ca
|
BDO Canada LLP
222 Bay Street
Suite 2200, PO Box 131
Toronto ON M5K 1H1 Canada
|
Note
|
December 31, 2020
|
December 31, 2019
|
|||||||||
Assets
|
|||||||||||
Current Assets:
|
|||||||||||
Cash and cash equivalents
|
$
|
25,468,805
|
$
|
814,492
|
|||||||
Amounts receivable
|
71,566
|
84,097
|
|||||||||
Deposits
|
765,599
|
481,400
|
|||||||||
Prepaid expense
|
642,214
|
369,453
|
|||||||||
Total Current Assets
|
$
|
26,948,184
|
$
|
1,749,442
|
|||||||
Property, plant, and equipment
|
3
|
245,372
|
-
|
||||||||
Right of use assets - leases
|
4
|
866,601
|
30,394
|
||||||||
Patent rights
|
5
|
1,777,978
|
1,601,745
|
||||||||
Total Assets
|
$
|
29,838,135
|
$
|
3,381,581
|
|||||||
Liabilities
|
|||||||||||
Current Liabilities:
|
|||||||||||
Accounts payable and accrued liabilities
|
6
|
$
|
4,528,890
|
$
|
11,412,896
|
||||||
Current portion of lease liability
|
4
|
165,768
|
21,071
|
||||||||
Note payable
|
7
|
1,885,497
|
$
|
-
|
|||||||
Warrant liability
|
8
|
36,316,681
|
3,621,444
|
||||||||
Total Current Liabilities
|
$
|
42,896,836
|
$
|
15,055,411
|
|||||||
Long-term lease liability
|
4
|
750,791
|
8,001
|
||||||||
Total Liabilities
|
$
|
43,647,627
|
$
|
15,063,412
|
|||||||
Shareholders' Deficiency
|
|||||||||||
Share capital
|
9
|
$
|
215,819,053
|
$
|
194,859,415
|
||||||
Contributed surplus
|
9,400,885
|
8,303,527
|
|||||||||
Deficit
|
(239,029,430
|
)
|
(214,844,773
|
)
|
|||||||
Shareholders' Deficiency
|
$
|
(13,809,492
|
)
|
$
|
(11,681,831
|
)
|
|||||
Total Liabilities and Deficiency
|
$
|
29,838,135
|
$
|
3,381,581
|
Commitments (Note 11)
|
Subsequent events (Note 17)
|
See notes to the consolidated financial statements
|
Approved on behalf of the Board:
|
"signed"
|
"signed"
|
|
Paul Cataford
|
David McNally
|
|
Director
|
Chairman and CEO
|
Note
|
December 31, 2020
|
December 31, 2019
|
|||||||||
Revenue
|
$
|
20,000,000
|
$
|
-
|
|||||||
Expenses
|
|||||||||||
Amortization
|
$
|
236,842
|
$
|
32,555
|
|||||||
Consulting fees
|
536,968
|
1,136,146
|
|||||||||
Foreign exchange loss (gain)
|
113,972
|
37,972
|
|||||||||
Impairment of patent rights
|
5
|
45,981
|
-
|
||||||||
Insurance
|
698,961
|
480,362
|
|||||||||
Interest charges
|
1,091,216
|
422,989
|
|||||||||
Management salaries and fees
|
2,549,924
|
2,547,484
|
|||||||||
Marketing and investor relations
|
140,976
|
289,350
|
|||||||||
Office and general
|
385,163
|
436,051
|
|||||||||
Professional fees
|
2,150,958
|
943,535
|
|||||||||
Rent
|
41,320
|
58,064
|
|||||||||
Research and development
|
7,937,171
|
51,418,056
|
|||||||||
Stock based compensation
|
9 b
|
|
1,097,358
|
1,651,119
|
|||||||
Travel
|
27,622
|
272,594
|
|||||||||
$
|
17,054,432
|
$
|
59,726,277
|
||||||||
Net Earnings (Loss) from Operations
|
2,945,568
|
(59,726,277
|
)
|
||||||||
Finance Income (Cost)
|
|||||||||||
Interest received from investments
|
$
|
29,143
|
$
|
115,584
|
|||||||
Gain on settlements
|
6
|
2,512,626
|
-
|
||||||||
Gain (loss) on change in fair value of warrants
|
8
|
(27,855,678
|
)
|
19,800,645
|
|||||||
Warrant liability issue cost
|
(1,816,316
|
)
|
(2,097,031
|
)
|
|||||||
$
|
(27,130,225
|
)
|
$
|
17,819,198
|
|||||||
Net and Comprehensive Loss
|
$
|
24,184,657
|
$
|
41,907,079
|
|||||||
Basic and Diluted Loss per Share
|
$
|
0.36
|
$
|
1.37
|
|||||||
Weighted Average Number of Common Shares
|
|||||||||||
Basic and Diluted
|
67,008,897
|
30,689,545
|
|||||||||
See notes to the consolidated financial statements
|
Note
|
Share Capital
Number
|
Share Capital
Amount
|
Contributed
Surplus
|
Deficit
|
Total
Deficiency
|
||||||||||||||||||
Balance - December 31, 2018
|
21,675,849
|
$
|
170,502,394
|
$
|
6,652,409
|
$
|
(172,937,694
|
)
|
$
|
4,217,109
|
|||||||||||||
Issued pursuant to agency agreement
|
9 a
|
|
8,455,882
|
13,717,131
|
-
|
-
|
13,717,131
|
||||||||||||||||
Issued pursuant to private placements
|
9 a
|
|
8,757,444
|
5,727,971
|
-
|
-
|
5,727,971
|
||||||||||||||||
Share issue expense
|
-
|
(2,090,124
|
)
|
-
|
-
|
(2,090,124
|
)
|
||||||||||||||||
Warrants exercised during the year
|
9 a
|
|
1,018,506
|
7,002,043
|
-
|
-
|
7,002,043
|
||||||||||||||||
Stock based compensation
|
9 b
|
|
-
|
-
|
1,651,118
|
-
|
1,651,118
|
||||||||||||||||
Net and comprehensive loss
|
-
|
-
|
-
|
(41,907,079
|
)
|
(41,907,079
|
)
|
||||||||||||||||
Balance - December 31, 2019
|
39,907,681
|
$
|
194,859,415
|
$
|
8,303,527
|
$
|
(214,844,773
|
)
|
$
|
(11,681,831
|
)
|
Balance - December 31, 2019
|
39,907,681
|
$
|
194,859,415
|
$
|
8,303,527
|
$
|
(214,844,773
|
)
|
$
|
(11,681,831
|
)
|
||||||||||||
Issued pursuant to agency agreement1
|
9 a
|
|
23,923,700
|
12,818,657
|
-
|
-
|
12,818,657
|
||||||||||||||||
Share issue expense
|
-
|
(487,788
|
)
|
-
|
-
|
(487,788
|
)
|
||||||||||||||||
Common stock equivalents converted
|
9 a
|
|
11,500,000
|
1,150
|
-
|
-
|
1,150
|
||||||||||||||||
Warrants exercised during the year
|
9 a
|
|
7,853,462
|
8,627,619
|
-
|
-
|
8,627,619
|
||||||||||||||||
Stock based compensation
|
9 b
|
|
-
|
-
|
1,097,358
|
-
|
1,097,358
|
||||||||||||||||
Net and comprehensive loss
|
-
|
-
|
-
|
(24,184,657
|
)
|
(24,184,657
|
)
|
||||||||||||||||
Balance - December 31, 2020
|
83,184,843
|
$
|
215,819,053
|
$
|
9,400,885
|
$
|
(239,029,430
|
)
|
$
|
(13,809,492
|
)
|
1. Includes net proceeds from the issuance of common share equivalents (see note 9 a)
|
See notes to the consolidated financial statements
|
Note
|
December 31, 2020
|
December 31, 2019
|
|||||||||
Cash provided by (used in):
|
|||||||||||
Operating activities:
|
|||||||||||
Net and comprehensive loss
|
$
|
(24,184,657
|
)
|
$
|
(41,907,079
|
)
|
|||||
|
|||||||||||
Items not involving cash:
|
|||||||||||
Amortization
|
236,842
|
32,555
|
|||||||||
Impairment of patent rights
|
45,981
|
-
|
|||||||||
Non-cash interest on lease
|
36,274
|
-
|
|||||||||
Stock based compensation
|
1,097,358
|
1,651,119
|
|||||||||
Warrant liability-fair value adjustment
|
27,855,678
|
(19,800,645
|
)
|
||||||||
Warrant liability-foreign exchange adjustment
|
95,631
|
17,687
|
|||||||||
Non-cash issue costs
|
764,132
|
744,501
|
|||||||||
Non-cash settlements
|
6, 9 a
|
|
(2,262,052
|
)
|
-
|
||||||
Non-cash note payable expenses and accrued interest
|
385,496
|
-
|
|||||||||
Changes in non-cash working capital items:
|
|||||||||||
Amounts receivable, prepaid expenses and deposits
|
(544,429
|
)
|
8,336,486
|
||||||||
Accounts payable and accrued liabilities
|
(4,371,371
|
)
|
4,965,008
|
||||||||
Cash used in operating activities
|
(845,117
|
)
|
(45,960,368
|
)
|
|||||||
Financing activities:
|
|||||||||||
Net proceeds from issuance of common shares and warrants1
|
24,688,851
|
35,766,754
|
|||||||||
Note payable
|
1,500,000
|
-
|
|||||||||
Repayment of lease liabilities
|
(90,053
|
)
|
(5,100
|
)
|
|||||||
Cash provided by financing activities
|
26,098,798
|
35,761,654
|
|||||||||
Investing Activities:
|
|||||||||||
Purchase of property, plant and equipment
|
(280,410
|
)
|
-
|
||||||||
Cost of patents
|
(318,958
|
)
|
(458,037
|
)
|
|||||||
Cash used in investing activities
|
(599,368
|
)
|
(458,037
|
)
|
|||||||
Increase (decrease) in cash and cash equivalents
|
24,654,313
|
(10,656,751
|
)
|
||||||||
Cash and cash equivalents, beginning of the period
|
814,492
|
11,471,243
|
|||||||||
Cash and cash equivalents, end of the period
|
$
|
25,468,805
|
$
|
814,492
|
|||||||
Cash and cash equivalents comprise:
|
|||||||||||
Cash
|
$
|
1,302,037
|
$
|
141,768
|
|||||||
Cash equivalents
|
24,166,768
|
672,724
|
|||||||||
$
|
25,468,805
|
$
|
814,492
|
1. Includes net proceeds from the issuance of common share equivalents - see note 9 a.
|
See notes to the consolidated financial statements
|
(a) |
Statement of Compliance
|
(b) |
Basis of Measurement
|
(c) |
Basis of Consolidation
|
(d) |
Functional and Presentation Currency
|
1. |
DESCRIPTION OF BUSINESS (continued)
|
(e) |
Use of Estimates and Judgements
|
|
• |
incremental borrowing rate used to measure lease liabilities
|
|
• |
fair value estimate of the measurement of leases and warrant liabilities
|
(f) |
COVID-19
|
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
(a) |
Cash and Cash Equivalents
|
(b) |
Property, plant, and equipment
|
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
|
|
Computer equipment
|
3 years |
|
|
|
|
Furniture and fixtures | 3 years |
|
|
|
|
Machinery | 3 years |
Leasehold improvements | Remaining term of the lease |
(c) |
Leases
|
(d) |
Patent Rights
|
(e) |
Impairment of Long-Lived Assets
|
(f) |
Deferred Income Taxes
|
(g) |
Foreign Currency
|
(h) |
Warrant Liability
|
(i) |
Fair Value Measurement
|
(j) |
Stock-Based Compensation
|
(k) |
Research and Development Costs
|
(l) |
Investment Tax Credits
|
(m) |
Financial Instruments
|
(n) |
Revenue Recognition
|
(o) |
Short-term Employee Benefits
|
(p) |
Provisions
|
(q) |
Earnings (Loss) per Share
|
(r) |
Adoption of New Accounting Standard
|
|
• |
IAS 1 Presentation of Financial Statements and IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors (Amendment – Disclosure
Initiative – Definition of Material;
|
|
• |
Revisions to the Conceptual Framework for Financing Reporting;
|
|
• |
Definition of a Business (Amendments to IFRS 3);
|
|
• |
Interest Rate Benchmark Reform – IBOR ‘phase 2’ (Amendments to IFRS 9 and IAS 39) and
|
|
• |
COVID-19 – Related Rent Concessions (Amendments to IFRS 16).
|
(s) |
Standards, Amendments, and Interpretations not yet Effective
|
3. |
PROPERTY, PLANT, AND EQUIPMENT
|
For the year ended December 31, 2020
|
Cost
|
Accumulated
depreciation
|
Net Book
Value
|
|||||||||
Computer equipment
|
||||||||||||
Balance at December 31, 2019
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Additions
|
49,721
|
-
|
49,721
|
|||||||||
Depreciation in the year
|
-
|
(12,827
|
)
|
(12,827
|
)
|
|||||||
Furniture and fixtures
|
||||||||||||
Balance at December 31, 2019
|
-
|
-
|
-
|
|||||||||
Additions
|
53,689
|
-
|
53,689
|
|||||||||
Depreciation in the year
|
-
|
(20,352
|
)
|
(20,352
|
)
|
|||||||
Leasehold improvements
|
||||||||||||
Balance at December 31, 2019
|
-
|
-
|
-
|
|||||||||
Additions
|
23,619
|
-
|
23,619
|
|||||||||
Depreciation in the year
|
-
|
(1,858
|
)
|
(1,858
|
)
|
|||||||
Machinery
|
||||||||||||
Balance at December 31, 2019
|
-
|
-
|
-
|
|||||||||
Additions
|
153,380
|
-
|
153,380
|
|||||||||
Depreciation in the year
|
-
|
-
|
-
|
|||||||||
Balance at December 31, 2020
|
$
|
280,409
|
$
|
(35,037
|
)
|
$
|
245,372
|
For the year ended December 31, 2019
|
Cost
|
Accumulated
depreciation
|
Net Book
Value
|
|||||||||
Computer equipment
|
||||||||||||
Balance at December 31, 2018
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Furniture and fixtures
|
||||||||||||
Balance at December 31, 2018
|
-
|
-
|
-
|
|||||||||
Leasehold improvements
|
||||||||||||
Depreciation in the year
|
-
|
-
|
-
|
|||||||||
Machinery
|
||||||||||||
Balance at December 31, 2019
|
-
|
-
|
-
|
|||||||||
Balance at December 31, 2019
|
$
|
-
|
$
|
-
|
$
|
-
|
4. |
LEASES
|
Right of use assets
For the year ended December 31, 2020
|
Cost
|
Accumulated
amortization
|
Net Book
Value
|
|||||||||
Head Office
|
||||||||||||
Balance at December 31, 2019
|
$
|
34,172
|
$
|
(3,778
|
)
|
$
|
30,394
|
|||||
Amortization in the year
|
-
|
(22,670
|
)
|
(22,670
|
)
|
|||||||
Chapel Hill
|
||||||||||||
Balance at December 31, 2019
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Additions
|
941,268
|
-
|
941,268
|
|||||||||
Amortization in the year
|
-
|
(82,391
|
)
|
(82,391
|
)
|
|||||||
Balance at December 31, 2020
|
$
|
975,440
|
$
|
(108,839
|
)
|
$
|
866,601
|
For the year ended December 31, 2019
|
Cost
|
Accumulated
amortization
|
Net Book
Value
|
|||||||||
Head Office
|
||||||||||||
Balance at December 31, 2018
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||
Additions
|
34,172
|
-
|
34,172
|
|||||||||
Amortization in the year
|
-
|
(3,778
|
)
|
(3,778
|
)
|
|||||||
-
|
||||||||||||
Balance at December 31, 2019
|
$
|
34,172
|
$
|
(3,778
|
)
|
$
|
30,394
|
4. |
LEASES (continued)
|
Lease liabilities – maturity analysis
|
2020
|
2019
|
||||||
Less than one year
|
$
|
165,768
|
$
|
21,071
|
||||
One to three years
|
646,481
|
8,001
|
||||||
Four to five years
|
104,310
|
-
|
||||||
Total lease liabilities at December 31, 2020
|
$
|
916,559
|
$
|
29,072
|
5. |
PATENT RIGHTS
|
For the year ended December 31, 2020
|
Cost
|
Accumulated
Amortization
|
Net Book
Value
|
|||||||||
Balance at December 31, 2019
|
$
|
1,856,750
|
$
|
(255,005
|
)
|
$
|
1,601,745
|
|||||
Impairment losses
|
(45,981
|
)
|
-
|
(45,981
|
)
|
|||||||
Additions during the year
|
318,958
|
-
|
318,958
|
|||||||||
Amortization in the year
|
-
|
(96,744
|
)
|
(96,744
|
)
|
|||||||
Balance at December 31, 2020
|
$
|
2,129,727
|
$
|
(351,749
|
)
|
$
|
1,777,978
|
For the year ended December 31, 2019
|
Cost
|
Accumulated
Amortization
|
Net Book
Value
|
|||||||||
Balance at December 31, 2018
|
$
|
1,398,713
|
$
|
(226,228
|
)
|
$
|
1,172,485
|
|||||
Impairment losses
|
-
|
-
|
-
|
|||||||||
Additions during the year
|
458,037
|
-
|
458,037
|
|||||||||
Amortization in the year
|
-
|
(28,777
|
)
|
(28,777
|
)
|
|||||||
Balance at December 31, 2019
|
$
|
1,856,750
|
$
|
(255,005
|
)
|
$
|
1,601,745
|
6. |
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
|
7. |
NOTE PAYABLE
|
8. |
WARRANT LIABILITY
|
For the year ended December 31, 2020
|
Number of
Warrants
|
Amount
|
||||||
Opening Balance
|
21,203,411
|
$
|
3,621,444
|
|||||
Issue of warrants expiring, March 27, 2025
|
3,500,000
|
475,300
|
||||||
Issue of warrants expiring, November 6, 2025
|
2,757,252
|
508,200
|
||||||
Issue of warrants expiring, June 10, 2024
|
9,000,000
|
9,709,200
|
||||||
Warrants exercised during the year
|
(7,257,252
|
)
|
(5,948,771
|
)
|
||||
Warrants expired during the year
|
(233,740
|
)
|
(26,198
|
)
|
||||
Foreign exchange adjustment during the year
|
-
|
95,631
|
||||||
Fair value adjustment during the year
|
-
|
27,881,875
|
||||||
Balance at December 31, 2020
|
28,969,671
|
$
|
36,316,681
|
8. |
WARRANT LIABILITY (continued)
|
For the year ended December 31, 2019
|
Number of
Warrants
|
Amount
|
||||||
Opening Balance
|
13,901,859
|
$
|
11,250,167
|
|||||
Issue of warrants expiring, March 21, 2024
|
8,455,882
|
15,897,059
|
||||||
Warrants exercised during the year
|
(1,018,506
|
)
|
(3,742,824
|
)
|
||||
Warrants expired during the year
|
(135,824
|
)
|
-
|
|||||
Foreign exchange adjustment during the year
|
-
|
17,687
|
||||||
Fair value adjustment during the year
|
-
|
(19,800,645
|
)
|
|||||
Balance at December 31, 2019
|
21,203,411
|
$
|
3,621,444
|
Listed Warrants
|
Expiry date
|
Exercise
Price CDN$
|
Number issued
|
Number
outstanding
|
|||||||||
TMD.W.T.G
|
12-Feb-21
|
$
|
30.00
|
447,253
|
444,920
|
||||||||
TMD.W.T.H
|
31-Mar-21
|
$
|
36.00
|
577,106
|
577,106
|
||||||||
TMD.W.T.I
|
20-Sep-21
|
$
|
22.50
|
637,111
|
637,111
|
||||||||
Balance at December 31, 2020
|
1,661,470
|
1,659,137
|
Unlisted Warrants (in CDN$)
|
Expiry date
|
Exercise
Price CDN$
|
Number issued
|
Number
outstanding
|
|||||||||
March 2017
|
16-Mar-21
|
$
|
15.00
|
357,787
|
355,253
|
||||||||
June 2017
|
29-Jun-22
|
$
|
6.00
|
1,983,522
|
446,377
|
||||||||
August 2017
|
24-Aug-22
|
$
|
6.00
|
563,067
|
563,067
|
||||||||
December 2017
|
5-Dec-22
|
$
|
18.00
|
1,533,333
|
1,533,333
|
||||||||
April 2018
|
10-Apr-18
|
$
|
10.50
|
1,295,554
|
1,295,554
|
||||||||
Balance at December 31, 2020
|
5,733,263
|
4,193,584
|
Unlisted Warrants (in USD$)
|
Expiry date
|
Exercise
Price USD$
|
Number issued
|
Number
outstanding
|
|||||||||
August 20181
|
10-Aug-23
|
$
|
2.9200
|
7,679,574
|
6,661,068
|
||||||||
March 20192
|
21-Mar-24
|
$
|
3.9500
|
8,455,882
|
8,455,882
|
||||||||
March 2020
|
27-Mar-25
|
$
|
0.1900
|
3,500,000
|
-
|
||||||||
May 2020
|
6-Nov-25
|
$
|
0.3002
|
2,757,252
|
-
|
||||||||
June 2020
|
10-Jun-24
|
$
|
1.0000
|
9,000,000
|
8,000,000
|
||||||||
Balance at December 31, 2020
|
31,392,708
|
23,116,950
|
|||||||||||
Total Warrants Outstanding
|
38,787,441
|
28,969,671
|
9. |
SHARE CAPITAL
|
(a)
|
Authorized:
|
unlimited number of common shares, no par value
|
||
Issued:
|
83,184,843 (December 31, 2019: 39,907,681)
|
|
9. |
SHARE CAPITAL (continued)
|
Grant Date
|
Common shares
issued
|
Value
|
||||||
January 3, 2020
|
500,000
|
$
|
219,600
|
|||||
January 6, 2020
|
500,000
|
229,300
|
||||||
January 8, 2020
|
400,000
|
195,160
|
||||||
January 10, 2020
|
500,000
|
247,550
|
||||||
January 17, 2020
|
600,000
|
303,000
|
||||||
January 23, 2020
|
600,000
|
295,320
|
||||||
February 6, 2020
|
600,000
|
282,000
|
||||||
February 13, 2020
|
708,048
|
300,000
|
||||||
4,408,048
|
$
|
2,071,930
|
9. |
SHARE CAPITAL (continued)
|
Grant Date
|
Common shares
issued
|
Value
|
||||||
August 30, 2019
|
2,417,162
|
$
|
3,000,000
|
|||||
November 8, 2019
|
100,000
|
42,560
|
||||||
November 8, 2019
|
100,000
|
42,560
|
||||||
November 12, 2019
|
100,000
|
42,970
|
||||||
November 12, 2019
|
100,000
|
42,000
|
||||||
November 13, 2019
|
100,000
|
42,970
|
||||||
November 14, 2019
|
300,000
|
128,910
|
||||||
November 15, 2019
|
2,500,000
|
1,074,250
|
||||||
November 19, 2019
|
2,067,282
|
888,311
|
||||||
|
7,784,444
|
$
|
5,304,531
|
9. |
SHARE CAPITAL (continued)
|
(b) |
Stock Options and Compensation Options
|
Grant date / recipient
|
Number of
options
|
Exercise price
|
Vesting conditions
|
Contractual
life of
options
|
January 28, 2020, options
granted to a director
|
25,765
|
CDN $0.657
|
Options vest immediately
|
7 years
|
July 30, 2020, options granted
to a director
|
22,425
|
CDN $1.266
|
Options vest immediately
|
7 years
|
July 30, 2020, options granted
to employees
|
1,350,000
|
USD $0.962
|
Options vest as to ¼ of the total
number of options granted,
every year from grant date
|
7 years
|
September 29, 2020, options
granted to board members
|
27,304
19,568
|
CDN $0.960
USD $0.730
|
Options vest immediately
|
7 years
|
September 30, 2020, options
granted to a consultant
|
4,723
|
USD $0.745
|
Options vest immediately
|
3 years
|
December 10, 2020, options
granted to employees
|
4,000
623,000
|
CDN $1.700
USD $1.310
|
Options vest as to ¼ of the total
number of options granted,
every year from grant date
|
7 years
|
9. |
SHARE CAPITAL (continued)
|
STOCK OPTIONS OUTSTANDING
|
CANADIAN DOLLAR
|
UNITED STATES DOLLAR
|
||||||||||||||
Number
stock
options
|
Weighted
Average
Exercise Price
|
Number of
stock
options
|
Weighted
Average
Exercise Price
|
|||||||||||||
Balance at December 31, 2019
|
860,379
|
$
|
5.89
|
854,042
|
$
|
2.65
|
||||||||||
Granted
|
79,494
|
0.99
|
1,997,291
|
0.96
|
||||||||||||
Expired / forfeited
|
(105,908
|
)
|
8.39
|
(761,528
|
)
|
2.66
|
||||||||||
Balance at December 31, 2020
|
833,965
|
$
|
5.10
|
2,089,805
|
$
|
1.13
|
CANADIAN DOLLAR
|
UNITED STATES DOLLAR
|
|||||||||||||||
Number
stock
options
|
Weighted
Average
Exercise Price
|
Number of
stock
options
|
Weighted
Average
Exercise Price
|
|||||||||||||
Balance at December 31, 2018
|
875,433
|
$
|
18.20
|
50,349
|
$
|
1.55
|
||||||||||
Granted
|
35,719
|
4.54
|
843,693
|
2.72
|
||||||||||||
Expired / forfeited
|
(50,773
|
)
|
31.79
|
(40,000
|
)
|
3.72
|
||||||||||
Balance at December 31, 2019
|
860,379
|
$
|
5.89
|
854,042
|
$
|
2.65
|
9. |
SHARE CAPITAL (continued)
|
Canadian Dollar Denominated Options
|
||||||||||||
Exercise Price (CDN)
|
Number
Outstanding
|
Weighted-average remaining
contractual life (years)
|
Options Exercisable
|
|||||||||
$0.66
|
25,765
|
6.08
|
25,765
|
|||||||||
$0.96
|
27,304
|
6.75
|
27,304
|
|||||||||
$1.27
|
22,425
|
6.58
|
22,425
|
|||||||||
$1.70
|
4,000
|
6.95
|
-
|
|||||||||
$3.28
|
31,498
|
4.66
|
31,498
|
|||||||||
$4.54
|
682,422
|
3.09
|
360,237
|
|||||||||
$9.00
|
11,481
|
4.52
|
11,481
|
|||||||||
$30.00
|
28,260
|
0.65
|
28,260
|
|||||||||
$32.40
|
810
|
0.07
|
810
|
|||||||||
833,965
|
3.61
|
507,780
|
United States Dollar Denominated Options
|
||||||||||||
Exercise Price (USD)
|
Number
Outstanding
|
Weighted-average remaining
contractual life (years)
|
Options Exercisable
|
|||||||||
$0.73
|
19,568
|
6.75
|
19,568
|
|||||||||
$0.75
|
4,723
|
2.75
|
4,723
|
|||||||||
$0.96
|
1,350,000
|
6.58
|
-
|
|||||||||
$1.31
|
623,000
|
6.95
|
-
|
|||||||||
$1.55
|
50,349
|
0.96
|
50,349
|
|||||||||
$2.20
|
2,165
|
5.55
|
2,165
|
|||||||||
$3.72
|
40,000
|
1.69
|
-
|
|||||||||
2,089,805
|
6.45
|
76,805
|
||||||||||
Total
|
2,923,770
|
5.64
|
584,585
|
9. |
SHARE CAPITAL (continued)
|
CANADIAN DOLLARS
|
UNITED STATES DOLLARS
|
||||||||||||
2020
|
2019
|
2020
|
2019
|
||||||||||
Fair value at grant
|
$
|
0.82
|
1.61
|
0.89
|
1.48
|
||||||||
Share price at grant
|
1.01
|
2.90
|
1.04
|
2.36
|
|||||||||
Exercise price
|
1.04
|
4.54
|
1.07
|
2.72
|
|||||||||
Expected option life
|
4 years
|
3.4 years
|
4.0 years
|
3.5 years
|
|||||||||
Risk free interest rate
|
0.67%
|
|
1.43%
|
|
0.29%
|
|
1.50%
|
|
|||||
Expected volatility
|
145.61%
|
|
98.10%
|
|
149.77
|
97.90%
|
|
||||||
Expected dividends
|
Nil
|
Nil
|
Nil
|
Nil
|
(c) |
Warrants
|
Expiry date
|
Exercise
Price
|
Outstanding
at
December
31, 20191
|
Issued
|
Exercised
|
Expired
|
Outstanding
at December
31, 20201
|
||||||||||||||||||
April 12, 2020
|
$
|
9.00000
|
89,795
|
-
|
-
|
(89,795
|
)
|
-
|
||||||||||||||||
August 10, 2020
|
$
|
2.50000
|
537,570
|
-
|
-
|
(537,570
|
)
|
-
|
||||||||||||||||
March 21, 2021
|
$
|
3.40000
|
591,911
|
-
|
-
|
-
|
591,911
|
|||||||||||||||||
June 10, 2024
|
$
|
1.25000
|
-
|
1,260,000
|
-
|
-
|
1,260,000
|
|||||||||||||||||
March 27, 2025
|
$
|
0.21250
|
-
|
490,000
|
(335,650
|
)
|
-
|
154,350
|
||||||||||||||||
November 6, 2025
|
$
|
0.45335
|
-
|
386,015
|
(260,560
|
)
|
-
|
125,455
|
||||||||||||||||
Ending balance
|
1,219,276
|
2,136,015
|
(596,210
|
)
|
(627,365
|
)
|
2,131,716
|
10. |
INCOME TAXES
|
(a) |
Current income taxes
|
December 31, 2020
|
December 31, 2019
|
|||||||
Net loss before income taxes
|
$
|
(24,184,657
|
)
|
$
|
(41,907,079
|
)
|
||
Income taxes at statutory rates
|
(6,408,934
|
)
|
(11,105,376
|
)
|
||||
Tax effect of expenses not deductible for income tax purposes:
|
||||||||
Permanent differences
|
7,648,554
|
(4,800,780
|
)
|
|||||
Unrecognized share issue costs
|
(129,264
|
)
|
(625,220
|
)
|
||||
Tax / foreign rate changes and other adjustments
|
(49,409
|
)
|
93,724
|
|||||
Total tax recovery
|
1,060,947
|
(16,437,652
|
)
|
|||||
Tax recovery not recognized
|
(1,060,947
|
)
|
16,437,652
|
|||||
$
|
-
|
$
|
-
|
(b) |
Deferred income taxes
|
December 31, 2020
|
December 31, 2019
|
|||||||
Non-capital losses
|
$
|
62,773,915
|
$
|
63,740,497
|
||||
Qualifying research and development expenditure
|
1,493,309
|
1,493,309
|
||||||
Share issue costs and other
|
1,868,633
|
1,999,584
|
||||||
Total tax assets
|
66,135,857
|
67,233,390
|
||||||
Tax assets not recognized
|
(66,135,857
|
)
|
(67,233,390
|
)
|
||||
Net deferred tax assets
|
$
|
-
|
$
|
-
|
10. |
INCOME TAXES (continued)
|
(c) |
Losses carried forward
|
Expiry year
|
Non-capital losses
|
||||
2031
|
$
|
9,674,326
|
|||
2032
|
10,454,774
|
||||
2033
|
10,210,370
|
||||
2034
|
13,784,437
|
||||
2035
|
43,934,918
|
||||
2036
|
28,260,911
|
||||
2037
|
19,604,159
|
||||
2038
|
40,239,997
|
||||
2039
|
60,718,805
|
||||
$
|
236,882,697
|
(d) |
Investment tax credits
|
11. |
COMMITMENTS
|
12. |
RELATED PARTY TRANSACTIONS
|
1. |
Monique Delorme was appointed Chief Financial Officer on October 1, 2020.
|
2. |
Stephen Randall retired as Chief Financial Officer on September 30, 2020. He remains on the board of directors.
|
3. |
John Barker retired as directors effective September 30, 2020.
|
4. |
John Schellhorn retired as a director effective June 4, 2020.
|
13. |
FINANCIAL INSTRUMENTS
|
(a) |
Credit risk
|
(b) |
Liquidity risk
|
13. |
FINANCIAL INSTRUMENTS (continued)
|
(c) |
Market risk
|
|
i. |
Interest rate risk
|
|
ii. |
Foreign currency risk
|
(d) |
Sensitivity analysis
|
13. |
FINANCIAL INSTRUMENTS (continued)
|
5% strengthening
|
December 31, 2020
|
December 31, 2019
|
||||||
Canadian dollar current assets
|
$
|
(7,659
|
)
|
$
|
(19, 687
|
)
|
||
Canadian dollar accounts payable and accrued liabilities
|
226,669
|
52,228
|
||||||
Change in profit (loss)
|
$
|
219,010
|
$
|
32,541
|
14. |
REVENUES
|
15. |
SEGMENTED REPORTING
|
16. |
CAPITAL MANAGEMENT
|
17. |
SUBSEQUENT EVENTS
|
(a) |
Warrants exercised
|
(b) |
Options exercised
|
(c) |
Equity offerings
|
17. |
SUBSEQUENT EVENTS (continued)
|
Exhibit 99.3
|
|
• |
the Company’s ability to raise sufficient financing on a timely basis, and attract and retain qualified personnel;
|
|
• |
the adverse impact on the Company’s contractors and suppliers’ ability to meet their obligations to the Company as a result of COVID-19;
|
|
• |
The Company’s business consists of the design and development of robotic-assisted surgical technologies for application in MIS and is presently focused on the development of the Enos™ robotic single access
surgical system (the “Enos system”) and development under the Development Agreement (as defined herein);
|
|
• |
the Enos under development includes a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing minimally invasive surgery (“MIS”)
procedures;
|
|
• |
the Enos system under development includes a surgeon workstation that provides the surgeon with an ergonomic interface to the patient cart and a 3D high-definition view of the MIS procedures;
|
|
• |
the Company’s intent to initially pursue gynecologic surgical indications for use of its Enos system;
|
|
• |
the Company’s plan to continue development of a robust training curriculum and post-training assessment tools for surgeons and surgical teams;
|
|
• |
the Company’s training curriculum is planned to include cognitive pre-training, psychomotor skills training, surgery simulations, live animal and human cadaver lab training, surgical team training, troubleshooting
and an overview of safety;
|
|
• |
the Company’s post-training assessment will include validation of the effectiveness of those assessment tools;
|
|
• |
the Company’s filing and prosecution of patents will validate the novelty of its unique technology and support the value of the entire franchise;
|
|
• |
the performance of human surgeries with the Enos system will require an Investigational Device Exemption (“IDE”) from the Food and Drug Administration (“FDA”), which must be submitted and approved in advance;
|
|
• |
the need for further Good Laboratory Practice (“GLP”) and human factors evaluation (“HFE”) preclinical studies to demonstrate the safety and performance of the system prior to proceeding with IDE clinical studies;
|
|
• |
the recruitment of surgeons from multiple hospital sites will be necessary to perform the surgeries. Each of these sites will require approval of their independent Institutional Review Board (“IRB”) to approve the
studies;
|
|
• |
that an application to the IRB of each hospital will be made once the FDA has approved the Company’s IDE application;
|
|
• |
the Company will likely proceed with a De Novo classification request for the Enos system, while continuing to evaluate its options for use of the 510(k) submission pathway;
|
|
• |
the Company’s intention to continue with the De Novo classification process if the 510(k) pathway is not available to the Company;
|
|
• |
the outcome of any review by the FDA and the time required to complete activities necessary for regulatory approval or clearance;
|
|
• |
the Company’s plan to file one or more additional Pre-Submissions with the FDA to allow it to review specific aspects of the design of the Company’s surgical system, the intended use, and potential predicate
devices, in order to clarify the requirements for the IDE clinical study protocol, confirm the appropriate regulatory pathway, and/or understand any additional special controls which the FDA may apply;
|
|
• |
the Company’s ability to secure required capital to fund development and operating costs beyond 2022, in a timely manner;
|
|
• |
the Company has sufficient cash on hand to satisfy expected costs associated with the deliverables under Medtronic Milestone 3 and 4, as well as to satisfy the repayment of the Note when it becomes due;
|
|
• |
the Company may require additional funding to complete its submission of its application to the FDA for marketing authorization of its Enos system;
|
|
• |
the fact that the Company cannot produce an accurate estimate of the future costs of the development milestones and regulatory phases beyond the year 2022;
|
|
• |
the Company’s technology and research and development objectives and milestones, including any estimated costs, schedules for completion and probability of success and including without limitation the table set
forth herein under the heading, “Development Plan” and the footnotes thereunder;
|
|
• |
the indication of additional specific milestones as the development of the Enos system progresses;
|
|
• |
the Company’s plans to design, create and refine software for production system functionality of the Enos system and the estimated incremental costs (including the status, cost and timing of achieving the
development milestones disclosed herein);
|
|
• |
the Company’s plan to further expand its patent portfolio by filing additional patent applications as it progresses in the development of robotic-assisted surgical technologies and, potentially, by licensing
suitable technologies;
|
|
• |
the Company will receive a series of payments for Medtronic’s license to robotic assisted surgical technologies;
|
|
• |
the Company’s guidance on the regulatory process and the costs and time that may be involved, including whether it expects to or is required to proceed with a De Novo classification request;
|
|
• |
the Company’s expectations with respect to its relationship with its suppliers and product development firms;
|
|
• |
the engagement of certain contractors and suppliers and the assurance that those parties will all be agreeable to engage throughout the project on terms satisfactory to the Company;
|
|
• |
the Company will gradually transition to the new Enos system brand identity, including on its website and in presentations and other corporate material;
|
|
• |
the Company will transition to an updated corporate brand identity that, while retaining the Titan Medical name, complements the Enos robotic single access surgical system;
|
|
• |
the Company’s intentions to complete summative human factors studies and complete the design and development of the system and initiate clinical studies;
|
|
• |
the Company has sufficient capital on hand to complete Milestones 3 through 9 of the table noted under “Development Plan”;
|
|
• |
the Company expects to be able to continue operations for 16 months and complete Milestones 3 through 14, with its current financial resources and the net proceeds from the February 2021 Offering;
|
|
• |
with the Company’s current financial resources and the net proceeds from the February 2021 Offering, the Company expects to have the financial resources to be able to continue operations for 22 months and complete
Milestones 3 through 16, if the Company achieves Medtronic Milestones 3 and 4 and receives the payments from Medtronic in respect of those milestones;
|
|
• |
the expected closing date of the the February 2021 Offering;
|
|
• |
the surgical indications for, and the benefits of, the Enos system;
|
|
• |
the Company’s seeking of licensing opportunities to expand its intellectual property portfolio;
|
|
• |
the Company’s industry and the markets in which it plans to operate or seeks to operate, including its general expectations and market position, market opportunities and market share;
|
|
• |
the Company’s ability to arrange further financing;
|
|
• |
the Company’s intention to confirm with the FDA the relevant regulatory pathway through the Pre-Submission process, and to initiate planning for the implementation of its IDE clinical studies;
|
|
• |
the Company’s expectation to implement improvements to its instruments, end-effectors and cameras and related modifications to the central unit of the patient cart, and complete software development for its Enos
system; and
|
|
• |
the Company’s intention with respect to updating any forward-looking statement after the date on which such statement is made or to reflect the occurrence of unanticipated events.
|
|
• |
dependency on additional financing;
|
|
• |
the Medtronic Loan (as defined herein) and the Note (as defined herein) may limit or preclude the Company from arranging further debt financing;
|
|
• |
the Company’s history of losses;
|
|
• |
reliance on strategic alliances;
|
|
• |
the ability to retain key personnel in a highly competitive employment environment;
|
|
• |
the possibility of the Company’s inability to augment its management team when required;
|
|
• |
the possibility that the Company’s trade secrets, and confidential information may be compromised;
|
|
• |
reliance on third parties for important aspects of the Company’s business;
|
|
• |
industry competitiveness;
|
|
• |
operating without infringement of intellectual property rights of others;
|
|
• |
obtaining and enforcing patent protection for the Company’s products;
|
|
• |
obtaining or maintaining our trademarks;
|
|
• |
conflicts of interest;
|
|
• |
fluctuating financial results;
|
|
• |
rapidly changing markets;
|
|
• |
introduction of more technologically advanced products by competitors;
|
|
• |
potential product liability claims;
|
|
• |
ability to license other intellectual property rights;
|
|
• |
government regulation;
|
|
• |
modifications to products requiring new regulatory clearance;
|
|
• |
extensive post-market regulation;
|
|
• |
the Company’s products causing or contributing to a death or serious injury;
|
|
• |
recalls by governmental authorities;
|
|
• |
compliance with accounting regulations and tax rules across multiple jurisdictions;
|
|
• |
contingent liabilities;
|
|
• |
sales cycle for the Enos system;
|
|
• |
uncertainty as to product development and commercialization milestones;
|
|
• |
uncertainties as to development and manufacturing of a commercially viable product;
|
|
• |
manufacturing delays, interruptions and cost overruns;
|
|
• |
reliance on external suppliers and development firms;
|
|
• |
delays, liability and negative perceptions from product malfunction;
|
|
• |
instruments, components and accessories require repeated cleaning and sterilization;
|
|
• |
commercial disputes;
|
|
• |
additional regulatory burden and controls over financial reporting;
|
|
• |
fluctuations in foreign currency;
|
|
• |
the possibility that the Company is not able to maintain its “foreign private issuer” status;
|
|
• |
the possibility of delisting from the Nasdaq or TSX exchanges;
|
|
• |
reduced disclosure requirements applicable to “emerging growth companies”;
|
|
• |
cyber-security risks and threats;
|
|
• |
adverse impact on the Company’s financial condition and results of operations as a result of COVID-19;
|
|
• |
current global financial conditions;
|
|
• |
results of operations;
|
|
• |
difficulties with forecasting future operating results;
|
|
• |
profitability;
|
|
• |
obligations as a public company;
|
|
• |
stock price volatility;
|
|
• |
possible future sales by the Company’s shareholders of their securities;
|
|
• |
limited operating history of the Company;
|
|
• |
the negative impact of COVID-19 on the ability of suppliers of goods and services to provide resources in a timely manner to support the Company’s milestones;
|
|
• |
the negative impact of COVID-19 on present and future demand for robotic-assisted surgeries, equipment, and supplies; and
|
|
• |
the negative impact of COVID-19 on the ability of the Company to obtain regulatory approvals as required on a timely basis to accomplish its milestones and objectives.
|
|
• |
general business and current global economic conditions;
|
|
• |
future success of current research and development activities;
|
|
• |
achieving development milestones;
|
|
• |
inability to achieve product cost targets;
|
|
• |
competition;
|
|
• |
potential changes to regulatory clearance processes in the United States and Europe;
|
|
• |
changes to tax rates and benefits;
|
|
• |
the availability of financing on a timely basis;
|
|
• |
the Company’s and competitors’ costs of production and operations;
|
|
• |
the Company’s ability to attract and retain skilled employees;
|
|
• |
the Company’s ongoing relations with its third-party service providers;
|
|
• |
the design of the Enos system and related platforms and equipment;
|
|
• |
the progress and timing of the development of the Enos system;
|
|
• |
costs related to the development of the Enos system;
|
|
• |
receipt of all applicable regulatory approvals/clearances;
|
|
• |
estimates and projections regarding the robotic-assisted surgery equipment industry;
|
|
• |
protection of the Company’s intellectual property rights;
|
|
• |
market acceptance of the Company’s systems under development;
|
|
• |
the Company’s ability to meet the continued listing standards of Nasdaq and the TSX; and
|
|
• |
the type of specialized skill and knowledge required to develop the Enos system and the Company’s access to such specialized skill and knowledge.
|
Milestone Number
|
Development Milestones
|
Estimated
Cost (US million $)(1) |
Schedule for Milestone Completion
|
Comments
|
Milestone 1
|
Design, prototype and test improvements to instruments, cameras and CDU
|
3.2
|
Q4 2020
|
Completed
|
Milestone 2
|
Launch rebranded product line including logos with trademark pending, literature and presentation templates and new website
|
0.3
|
Q4 2020
|
Completed
|
Milestone 3(4)
|
Iterate electromechanical design, update sterile adaptors and drape
|
5.2
|
Q1 2021
|
-
|
Milestone 4(4)
|
Perform additional software development and test system performance
|
5.4
|
Q1-Q2 2021
|
-
|
Milestone 5
|
Perform animal lab assessment
|
0.1
|
Q2 2021
|
-
|
Milestone 6(4)
|
Perform biocompatibility testing of instruments, camera systems and accessories at independent lab
|
3.8
|
Q2 2021
|
-
|
Milestone 7(4)
|
Perform electrical safety testing for surgeon workstations and patient cart, including electromagnetic compatibility (EMC) and electromagnetic interference (EMI) tests at independent lab
|
2.7
|
Q3 2021
|
-
|
Milestone 8(4)
|
Perform animal feasibility or GLP study
|
2.8
|
Q3 2021
|
-
|
Milestone 9(2)
|
Complete initial build of Enos system IDE units
|
10.2
|
Q4 2021
|
-
|
Milestone 10(2)(4)
|
Complete system verification testing
|
3.3
|
Q4 2021
|
-
|
Milestone 11(2)(4)
|
Complete HFE summative testing
|
1.9
|
Q4 2021
|
-
|
Milestone 12
|
Update application for IDE as additional testing lab data is received and continue preparation for human confirmatory studies
|
6.0
|
Q1 2022
|
-
|
Milestone 13
|
Submit IDE application to FDA
|
|||
Milestone 14
|
Complete secondary build of Enos system IDE units
|
|||
Milestone 15
|
Initiate IDE clinical study
|
19.0
|
Q2-Q4 2022
|
-
|
Milestone 16
|
Complete IDE clinical study, data analysis and final report
|
|||
Milestone 17(3)
|
Submit application for FDA marketing authorization
|
TBD
|
TBD(5)
|
-
|
Milestone 18
|
Tentative FDA marketing authorization letter
|
TBD
|
TBD
|
-
|
1.
|
The estimated costs above include an allocation of $1.8-2.8 million per quarter of general and administrative costs.
|
2.
|
Milestones 9, 10 and 11 are expected to be executed during the fourth quarter of 2021 with their projected completion in December 2021. If the Company achieves Medtronic Milestones 3 and 4, it
will be entitled to receive the corresponding payments from Medtronic of $10 million and $11 million, respectively, and assuming the completion of the February 2021 Offering, in those circumstances the Company estimates that
it will have sufficient funds for the execution and completion of Milestones 9, 10 and 11. If the Company does not achieve Medtronic Milestones 3 and 4, the Company will need to raise additional capital to complete Milestones
10 and 11.
|
3.
|
The Company anticipates proceeding with FDA marketing authorization as described in the section titled “The Business – Regulatory”.
|
4.
|
The costs of Milestones 1 through 11 are forecasted to total $38.9 million, a net increase of $1.6 million from amounts previously forecasted and published in the Company’s Management Discussion
and Analysis dated November 16, 2020. The increase is primarily related to general and administrative costs, enhancing internal R&D capabilities and other general R&D related costs.
|
5.
|
The timing of submittal of application for FDA marketing authorization will be determined at a future date, upon completion of IDE clinical studies and following further correspondence with the
FDA as described in the section titled “The Business – Regulatory”.
|
Medtronic Milestone(1)
|
Deadline(2)
|
Payment
(US$)(3) |
Medtronic Milestone 1
|
Four (4) months from Development Start Date(4) (5)
|
$10,000,000
|
Medtronic Milestone 2(6)
|
Four (4) months from Development Start Date
|
-
|
Medtronic Milestone 3
|
Six (6) months from the later of (a) receipt by us of Payment for Medtronic Milestone 1, (b) receipt by us from Medtronic of Medtronic deliverables required for
Medtronic Milestone 3, and (c) receipt by us from Medtronic of confirmation of certain due diligence in respect of our deliverables for Medtronic Milestone 1
|
$10,000,000
|
Medtronic Milestone 4
|
Four (4) months from the later of (a) receipt by us of Payment for Medtronic Milestone 3, (b) receipt by us of Medtronic deliverables for Medtronic Milestone
4, and (c) receipt by us from Medtronic of confirmation of certain due diligence in respect of our deliverables for Medtronic Milestone 3
|
$11,000,000 (7) (8)
|
1.
|
Medtronic Milestone 1, Medtronic Milestone 3 and Medtronic Milestone 4 are each defined in the Development Agreement and consist of the completion of the development of certain robotic assisted
surgical technologies as described in the Development Agreement.
|
2.
|
All as further described and qualified in the Development Agreement.
|
3.
|
Each payment is conditional upon the corresponding milestone being completed on a timely basis. As of the date of this document, Medtronic Milestone 1 has been achieved.
|
4.
|
“Development Start Date” has the meaning ascribed to it in the Development Agreement and as set out above.
|
5.
|
As of the date of this document, Medtronic Milestone 1 has been achieved on schedule and payment was received.
|
6.
|
Medtronic Milestone 2 is a non-technology milestone defined as Titan raising at least $18,000,000 of capital between the effective date of the Development Agreement and the date that is four
months from the Development Start Date. Medtronic Milestone 2 was achieved ahead of the deadline in June 2020.
|
7.
|
The amount of the payment will be the sum of $10,000,000 and the amount of certain legal, transaction and intellectual property related expenses to be paid to the Company up to a maximum of
$1,000,000 pursuant to the Development Agreement and License Agreement.
|
8.
|
The balance outstanding under the Medtronic Loan (described below) will be offset against the payment for Medtronic Milestone 4.
|
2020
|
2019
|
2018
|
|
Net sales
|
$20,000,000
|
-
|
-
|
Net and comprehensive loss
for the year
|
$24,184,657
|
$41,907,079
|
$22,639,272
|
Basic & diluted loss per share
|
$0.36
|
$1.37
|
$1.36
|
Total long-term liabilities
|
($750,791)
|
($8,001)
|
-
|
Total assets
|
$29,838,135
|
$3,381,581
|
$21,915,164
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
|
Research and Development Expenditures
|
$ 7,937,171
|
$ 51,418,056
|
For the quarter
|
Net sales
|
Net and comprehensive loss
(gain) from operations
|
Basic and diluted (gain)
loss per share
|
December 31, 2020
|
$10,000,000
|
$20,632,782
|
$0.25
|
September 30, 2020
|
-
|
$1,640,633
|
$0.02
|
June 30, 2020
|
$10,000,000
|
$1,143,199
|
$0.02
|
March 31, 2020
|
-
|
$768,043
|
$0.02
|
December 31, 2019
|
-
|
$(2,412,863)
|
$(0.07)
|
September 30, 2019
|
-
|
$1,564,196
|
$0.05
|
June 30, 2019
|
-
|
$14,472,866
|
$0.46
|
March 31, 2019
|
-
|
$28,282,880
|
$1.22
|
Contractual
Obligations
existing at the date
of this MD&A
|
Total
$
|
Less than 1 year
|
1 – 3 years
|
4 – 5 years
|
After 5 years
|
Lease liability
|
916,560
|
165,772
|
646,477
|
104,310
|
-
|
Note payable (1)
|
1,897,700
|
1,897,700
|
-
|
-
|
-
|
Supplier Agreement
|
1,500,000
|
1,500,000
|
-
|
-
|
-
|
Purchase order
commitments
|
10,390,483
|
10,390,483
|
-
|
-
|
-
|
Total Contractual
Obligations
|
14,704,743
|
13,953,955
|
646,477
|
104,310
|
-
|
1.
|
On April 28, 2020, the Company issued the Note to an affiliate of Medtronic for the Medtronic Loan and executed and delivered the Security Agreement. The Note is in the principal
amount of $1.5 million plus $296,046 equal to certain legal, transaction and intellectual property related expenses incurred by Medtronic pursuant to the Medtronic agreements plus $101,654 of accrued interest
to January 31, 2021. See “Recent Developments”.
|
Issue Date
|
Expiry Date
|
Number
Issued
|
Number
Outstanding
|
Exercise Price
US $
|
Exercise Price
CDN $
|
|
TMD.W.T.H
|
31-Mar-16
|
31-Mar-21
|
501,831
|
501,831
|
36.00
|
|
TMD.W.T.H
|
14-Apr-16
|
31-Mar-21
|
75,275
|
75,275
|
36.00
|
|
TMD.W.T.I
|
20-Sep-16
|
20-Sep-21
|
569,444
|
569,444
|
22.50
|
|
TMD.W.T.I
|
27-Oct-16
|
20-Sep-21
|
67,667
|
67,667
|
22.50
|
|
Not Listed
|
16-Mar-17
|
16-Mar-21
|
357,787
|
355,253
|
15.00
|
|
Not Listed
|
29-Jun-17
|
29-Jun-22
|
1,612,955
|
75,810
|
6.00
|
|
Not Listed
|
21-Jul-17
|
29-Jun-22
|
370,567
|
370,567
|
6.00
|
|
Not Listed
|
24-Aug-17
|
24-Aug-22
|
563,067
|
563,067
|
6.00
|
|
Not Listed
|
5-Dec-17
|
5-Dec-22
|
1,533,333
|
1,533,333
|
18.00
|
|
Not Listed
|
10-Apr-18
|
10-Apr-23
|
1,126,665
|
1,126,665
|
10.50
|
|
Not Listed
|
10-May-18
|
10-Apr-23
|
168,889
|
168,889
|
10.50
|
|
Not Listed1
|
10-Aug-18
|
10-Aug-23
|
7,679,574
|
6,661,068
|
2.9200
|
|
Not Listed2
|
21-Mar-19
|
21-Mar-24
|
8,455,882
|
8,455,882
|
3.9500
|
|
Not Listed
|
27-Mar-20
|
27-Mar-25
|
3,500,000
|
-
|
0.1900
|
|
Not Listed
|
6-May-20
|
6-Nov-25
|
2,757,252
|
-
|
0.3002
|
|
Not Listed
|
10-Jun-20
|
10-Jun-24
|
9,000,000
|
-
|
1.0000
|
|
Not Listed
|
26-Jan-21
|
26-Jan-26
|
3,709,677
|
3,126,427
|
2.0000
|
|
42,049,865
|
23,651,178
|
Note 1 - Includes a ratchet clause triggered August 29, 2019 lowering the exercise price from $3.20 to $2.92.
|
Note 2 - Includes a ratchet clause triggered August 29, 2019 lowering the exercise price from $4.00 to $3.95.
|
Date of Financing
|
Anticipated Use of Proceeds
|
Actual Use of Proceeds
|
March 25, 2020
|
General corporate purposes including resuming the
development of the single access robotic surgical system,
instruments, and accessories; funding working capital
(including the reduction of outstanding payables); and
capital expenditures.
|
As anticipated.
|
May 6, 2020
|
General corporate purposes including resuming the
development of the single access robotic surgical system,
instruments, and accessories; funding working capital
(including the reduction of outstanding payables); and
capital expenditures.
|
As anticipated.
|
June 10, 2020
|
General corporate purposes including resuming the
development of the single access robotic surgical system,
instruments, and accessories; funding working capital
(including the reduction of outstanding payables); and
capital expenditures.
|
As anticipated. The majority of
the proceeds are still available
for future periods. The Company
does not anticipate alternative
use of these proceeds.
|
Type of Securities
|
Number of Common Shares issued or
issuable upon conversion
|
Common Shares
|
99,939,390
|
Stock options(1)
|
2,894,392
|
Warrants
|
23,651,178
|
Broker warrants(2)
|
1,918,695
|
(1) |
The Company has outstanding options enabling certain employees, directors, officers, and consultants to purchase Common Shares:
|
|
• |
On January 28, 2020, the Company issued 25,765 stock options with an exercise price of CDN $0.657 to a director in exchange for services rendered. The options vest immediately and have a contractual life of 7
years.
|
|
• |
On July 30, 2020, the Company issued 22,425 stock options with an exercise price of CDN $1.266 to a director in exchange for services rendered. The options vest immediately and have a contractual life of 7
years.
|
|
• |
On July 30, 2020, the Company issued 1,350,000 stock options with an exercise price of US $0.962 to certain employees for services rendered. These options vest 25% annually over four years.
|
|
• |
On September 29, 2020, the Company issued 27,304 stock options with an exercise price of CDN $0.96 to a director in exchange for services rendered. The options vest immediately and have a contractual life of 7
years.
|
|
• |
On September 29, 2020, the Company issued 19,568 stock options with an exercise price of US $0.73 to a director in exchange for services rendered. The options vest immediately and have a contractual life of 7
years. Subsequent to December 31, 2020, these options were exercised.
|
|
• |
On September 30, 2020, the Company issued 4,723 stock options with an exercise price of US $0.745 to a consultant. The options vest immediately and have a contractual life of 3 years.
|
|
• |
On December 10, 2020, the Company issued 623,000 stock options with an exercise price of US $1.31 and 4,000 stock options with an exercise price of CDN $1.70 to certain employees for services rendered. These
options vest annually over four years and have a contractual life of 7 years.
|
(2) |
A total of 1,918,695 broker warrants previously issued in connection with offerings of securities by the Company in March 2019, March 2020, May 2020, June 2020 and January 2021 offerings remain outstanding:
|
|
• |
Pursuant to the agency agreement in respect of the March 2019 offering, in addition to the cash commission paid to the agents, 591,911 broker warrants were issued to the agents. Each broker warrant entitles
the holder thereof to acquire one common share at the price of US $3.40 for a period of 24 months following the closing date.
|
|
• |
Pursuant to the agency agreement in respect of the March 2020 offering, in addition to the cash commission paid to the agents, 490,000 broker warrants were issued to the agents. Each broker warrant entitles
the holder thereof to acquire one common share at the price of US $0.2125 for a period of 5 years following the closing date.
|
|
• |
Pursuant to the agency agreement in respect of the May 2020 offering, in addition to the cash commission paid to the agents, 386,015 broker warrants were issued to the agents. Each broker warrant entitles the
holder thereof to acquire one common share at the price of US $0.4534 for a period of five and one half (5.5) years following the closing date.
|
|
• |
Pursuant to the agency agreement in respect of the June 2020 offering, in addition to the cash commission paid to the agents, 1,260,000 broker warrants were issued to the agents. Each broker warrant entitles
the holder thereof to acquire one common share at the price of US $1.25 for a period of four years following the closing date.
|
|
• |
Pursuant to the January 2021 Offering, in addition to the cash commission paid to the agents, 519,354 broker warrants were issued to the agents. Each broker warrant entitles the holder thereof to acquire one
common share at the price of US $1.9375 for a period of 24 months following the closing date.
|
|
• |
Revenue from the License Agreement for intellectual property rights and know-how (“Royalty Payment”) is recognized when rights are granted, and customer acceptance is established. Compensation received for
the performance of technology transfer services relating to the License Agreement is accounted for separately from the Royalty Payment and will be recognized at the time the service is performed.
|
|
• |
Revenue from the Development Agreement and the allocation of ownership and license rights developed under each milestone is recognized when the rights are granted, and customer acceptance is established.
|
|
• |
Under the terms of the Development Agreement, payment is dependent on when the customer confirms completion of each milestone as defined. Due to the uncertainty of milestone achievements and entitlement of
payments, the Company recognizes revenue only upon acceptance by the customer of work performed and the milestone achieved.
|
Exhibit 99.4
|
Date: March 31, 2021
|
By: |
/s/
David McNally
David McNally President and Chief Executive Officer (Principal Executive Officer) |
Exhibit 99.5
|
Date: March 31, 2021 |
By:
|
/s/
Monique L. Delorme
Monique L. Delorme Chief Financial Officer (Principal Financial and Accounting Officer) |
Exhibit 99.6
|
March 31, 2021 |
/s/ David McNally
David McNally President and Chief Executive Officer (Principal Executive Officer) |
Exhibit 99.7
|
March 31, 2021 |
/s/ Monique L. Delorme
Monique L. Delorme Chief Financial Officer (Principal Financial and Accounting Officer) |
Exhibit 99.8
|